

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 November 2003 (27.11.2003)

PCT

(10) International Publication Number
WO 03/097586 A1

(51) International Patent Classification⁷: C07C 275/26,
275/32, 335/14, C07D 213/36, 215/38, 217/02, 217/08,
217/22, 217/24

(74) Agents: JOHNSON, Philip, S. et al.; JOHNSON &
JOHNSON, 1 JOHNSON & JOHNSON, PLAZA, New
Brunswick, NJ 08933 (US).

(21) International Application Number: PCT/US03/15254

(22) International Filing Date: 15 May 2003 (15.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/381,575 17 May 2002 (17.05.2002) US

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-
houtseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CODD, Ellen
[US/US]; 736 Cathcart Road, Blue Bell, PA 19422 (US).
DAX, Scott, L. [US/US]; 3 Quail Drive, Landenberg, PA
19350 (US). JETTER, Michele [US/US]; 3036 Bram-
bling Lane, Norristown, PA 19403 (US). MCDONELL,
Mark [US/US]; 1280 Sumneytown, Lansdale, PA 19446
(US). MCNALLY, James, J. [US/US]; 321 Heatherfield
Drive, Souderton, PA 18974 (US). YOUNGMAN, Mark
[US/US]; 675 East Street Road, Warminster, PA 18974
(US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 03/097586 A1

(54) Title: AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR



(57) Abstract: This invention is directed to vanilloid receptor
VR1 ligands of formula (1). More particularly, this invention
relates to β -aminotetralin-derived ureas that are potent antag-
onists or agonists of VR1 which are useful for the treatment
and prevention of inflammatory and other pain conditions in
mammals.

TITLE OF THE INVENTION
**AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1
RECEPTOR**

5

CROSS-REFERENCE TO RELATED APPLICATIONS

This applicaiton claims priority to United States Provisional Application
No. 60/381,575, filed May 17, 2003.

10

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT

The research and development of the invention described below was
15 not federally sponsored.

BACKGROUND OF THE INVENTION

20 This invention is directed to novel vanilloid receptor VR1 ligands. More particularly, this invention relates to novel β -aminotetralin-derived ureas that are potent antagonists or agonists of VR1 and exhibit activity in animal models of hyperalgesia and colitis, and are useful for the treatment and prevention of pain conditions in humans including arthritis, and for the treatment of irritable-
25 bowel syndrome and associated conditions.

Noxious chemical, thermal and mechanical stimuli excite peripheral nerve endings of small diameter sensory neurons (nociceptors) in sensory ganglia (e. g., dorsal root, nodose and trigeminal ganglia) and initiate signals
30 that are perceived as pain. These neurons are crucial for the detection of harmful or potentially harmful stimuli (heat) and tissue damage (local tissue acidosis and/or stretch) that arise from changes in the extracellular space during inflammatory or ischaemic conditions (Wall, P. D., and Melzack, R.,

Textbook of Pain, 1994, New York: Churchill Livingstone). Nociceptors transduce noxious stimuli into membrane depolarization that triggers action potential, conducts the action potential from the sensory sites to the synapses in the CNS, and conversion of action potentials invokes a perception of pain, discomfort, and appropriate mechanical/physical protective reflexes. At the molecular level, nociception is carried out by ion channels or receptors. Plant derived vanilloid compounds (capsaicin and its ultrapotent analog, resiniferatoxin, etc.) are known to selectively depolarize nociceptors and elicit sensations of burning pain — the sensation that is typically obtained by hot chili peppers. Therefore, capsaicin mimics the action of physiological/endogenous stimuli that activates the "nociceptive pathway". Recent advances in pain biology have identified receptors for vanilloids, protons (i.e., acidic solutions), and for heat. Because nociceptors are involved with unwanted pain and inflammatory conditions in human beings and animals, modulation of their nociceptive pathway is important in palliative and other therapies.

Walpole and colleagues at Sandoz reported on the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin (Walpole, C. S. J. et. al., *J. Med. Chem.* **1994**, 37, 1942). Subsequently, capsazepine has been shown to be a vanilloid receptor antagonist. Capsazepine, however, is not aminotetralin-derived. Jee Woo Lee and colleagues at Pacific Corporation disclosed thiocarbamic acid derived VR1 antagonists in WO0216317A1 and vanilloid receptor modulators in WO0216318A1 and WO0216319A1 but these applications do not disclose or describe α -substituted β -aminotetralins. Hutchinson and colleagues at Neurogen describe a diaryl piperazinyl ureas and related compounds as capsaicin receptor ligands in WO02082212A1 but aminotetralins are not covered. Scientists at the Universidad Miguel Hernandez in Alicante, the Universidad de Valencia and the Consejo Superior de Investigaciones Cientificas (CSIC) in Barcelona have used a combinatorial chemistry-based approach to discover compounds that modulate the vanilloid VR1 receptor and have disclosed two trialkylglycine-based compounds as noncompetitive VR1

channel blockers (Garcia-Martinez, C. et al. Proc Natl Acad Sci USA 2002, 99(4): 2374) but none are aminotetralin-derived.

5 US patents 6,140,354 and 6,201,025 by Dax et. al. teach the synthesis of N-acylated and N-alkylated α -substituted β -aminotetralins but do not describe the synthesis of ureido β -aminotetralins. US patent 6,169,116 B1 by Swoboda describes β -aminotetralins and their pharmaceutical uses but does not describe the synthesis of α -substituted β -aminotetralins and does not describe the synthesis of ureido β -aminotetralins. European patent application
10 0064964 by Arvidsson teaches the synthesis of N-alkylated α -alkyl- β -aminotetralins in which the alkyl substituent in the α -position is hydrogen or C₁₋₆alkyl but does not describe the synthesis of β -aminotetralins substituted with groups other than hydrogen or C₁₋₆alkyl in α -position nor describe the synthesis of ureido β -aminotetralins.


15

Thus, there is a need for potent modulators of VR, and in particular, for novel β -aminotetralin-derived ureas that exhibit potent binding affinity for the human and rat VR1 ion channel. There is also a need for novel β -aminotetralin-derived ureas that act as potent functional antagonists and/or agonists
20 of the human and rat VR1 ion channel. Finally, there is a need for novel β -aminotetralin-derived ureas that bind with high affinity to VR1 and also act as potent functional antagonists of the human and rat VR1 ion channel.

25

SUMMARY OF THE INVENTION

The present invention is directed to compositions comprising a compound of Formula (I):



Formula (I)

wherein:

- R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; formyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; $(C_{1-8}$ alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C_{1-8} alkanyl)carbonyl;
- n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R_2 is independently selected from the group consisting of hydrogen; hydroxy; C_{1-8} alkanyl; C_{2-8} alkenyl; C_{2-8} alkenyl; C_{1-8} alkylidenyl; C_{1-8} alkylidynyl; fluoro; chloro; C_{3-8} cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy, phenyl(C_{1-8} alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C_{1-8} alkanylamino, and C_{1-8} dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy, phenyl(C_{1-8} alkanyloxy, fluorinated alkanyl, cyano, nitro, amino,

C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents
 5 independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

10 R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently
 15 selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is
 20 quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

25 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

Preferred embodiments of the present invention are those in
 30 which: (1) R₁ is a substituent independently selected from the group consisting of hydrogen, hydroxy, fluoro, chloro, bromo, and C₁₋₈alkanyloxy; (2) R₁ is a substituent independently selected from the group consisting of fluoro, chloro, bromo, C₁₋₈alkanyloxy, (3) R₂ is independently selected from the group

consisting of hydrogen, C₂₋₈alkenyl, C₂₋₈alkenyl, C₁₋₈alkylidenyl, C₁₋₈alkylidynyl, C₃₋₈cycloalkanyl, phenyl (optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl), naphthyl (optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl), and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein the heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; (4) L is a direct bond or C₁₋₈alkanylene; and (5) R₃ is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro, quinolinyl-N-oxide, isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyl-N-oxide.

Finally, the present invention is directed to pharmaceutical compositions containing compounds of Formula (I), as well as to methods of treatment of diseases and conditions by administration of these compositions, and also to pharmaceutical kits containing them.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the IC₅₀ values of the competitive vanilloid antagonist capsazepine for inhibition of calcium flux induced by a number of different stimuli known to activate VR1.

Figure 2 shows the IC₅₀ values for inhibition by a compound of the invention of the calcium flux induced by a number of different stimuli known to activate VR1.

Figure 3 shows inhibition by a compound of the invention of capsaicin-induced contraction of guinea pig bronchial rings in an isolated tissue assay.

Figure 4 shows inhibition by another compound of the invention of capsaicin-induced contraction of guinea pig bronchial rings in an isolated tissue assay.

5 DETAILED DESCRIPTION OF THE INVENTION

As used herein, the following underlined terms are intended to have the following meanings:

10 "C_{a-b}" (where *a* and *b* are integers) refers to a radical containing from *a* to *b* carbon atoms inclusive. For example, C₁₋₃ denotes a radical containing 1, 2 or 3 carbon atoms.

15 "Fluorinated alkyl" refers to a saturated branched or straight chain hydrocarbon radical derived by removal of 1 hydrogen atom from the parent alkane; the parent alkane contains from 1 to 6 carbon atoms with 1 or more hydrogen atoms substituted with fluorine atoms up to and including substitution of all hydrogen atoms with fluorine. Preferred fluorinated alkyls include trifluoromethyl substituted alkyls and perfluorinated alkyls; more preferred
20 fluorinated alkyls include trifluoromethyl, perfluoroethyl, 2,2,2-trifluoroethyl, perfluoropropyl, 3,3,3-trifluoroprop-1-yl, 3,3,3-trifluoroprop-2-yl, 1,1,1,3,3,3-hexafluoroprop-2-yl; a particularly preferred fluorinated alkyl is trifluoromethyl.

25 "Fluorinated alkanyloxy" refers to a radical derived from a fluorinated alkyl radical attached to an oxygen atom with the oxygen atom having one open valence for attachment to a parent structure.

30 "Alkyl:" refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne. Typical alkyl groups include, but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl, cycloprop-1-en-1-yl; cycloprop-2-en-1-yl, prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, but-1-en-1-yl,

but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.; and the like.

- Where specific levels of saturation are intended, the nomenclature "alkanyl",
5 "alkenyl" and/or "alkynyl" is used, as defined below. In preferred embodiments, the alkyl groups are (C₁₋₈) alkyl, with (C₁₋₃) being particularly preferred.]

"Alkanyl:" refers to a saturated branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom
10 from a single carbon atom of a parent alkane. Typical alkanyl groups include, but are not limited to, methanyl; ethanyl; propanyls such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, etc.; butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, etc.; and the like. In preferred embodiments, the alkanyl groups are (C₁₋₈) alkanyl, with (C₁₋₃) being
15 particularly preferred.

"Alkenyl:" refers to an unsaturated branched, straight-chain or cyclic monovalent hydrocarbon radical having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom
20 of a parent alkene. The radical may be in either the *cis* or *trans* conformation about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl, prop-2-en-2-yl, cycloprop-1-en-1-yl; cycloprop-2-en-1-yl; butenyls such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl,
25 but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, etc.; and the like. In preferred embodiments, the alkenyl group is (C₂₋₈) alkenyl, with (C₂₋₃) being particularly preferred.

30 "Alkynyl:" refers to an unsaturated branched, straight-chain or cyclic monovalent hydrocarbon radical having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne. Typical alkynyl groups include, but are not limited to, ethynyl;

propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.; and the like. In preferred embodiments, the alkynyl group is (C₂₋₈) alkynyl, with (C₂₋₃) being particularly preferred.

5

"Alkyldiyl:" refers to a saturated or unsaturated, branched, straight-chain or cyclic divalent hydrocarbon radical derived by the removal of one hydrogen atom from each of two different carbon atoms of a parent alkane, alkene or alkyne, or by the removal of two hydrogen atoms from a single carbon atom of a parent alkane, alkene or alkyne. The two monovalent radical centers can form bonds with the same or different atoms. Typical alkyldiyls include, but are not limited to methandiyl; ethyldiyls such as ethan-1,1-diyl, ethan-1,2-diyl, ethen-1,1-diyl, ethen-1,2-diyl; propyldiyls such as propan-1,1-diyl, propan-1,2-diyl, propan-2,2-diyl, propan-1,3-diyl, cyclopropan-1,1-diyl, cyclopropan-1,2-diyl, prop-1-en-1,1-diyl, prop-1-en-1,2-diyl, prop-2-en-1,2-diyl, prop-1-en-1,3-diyl, cycloprop-1-en-1,2-diyl, cycloprop-2-en-1,2-diyl, cycloprop-2-en-1,1-diyl, prop-1-yn-1,3-diyl, etc.; butyldiyls such as, butan-1,1-diyl, butan-1,2-diyl, butan-1,3-diyl, butan-1,4-diyl, butan-2,2-diyl, 2-methyl-propan-1,1-diyl, 2-methyl-propan-1,2-diyl, cyclobutan-1,1-diyl; cyclobutan-1,2-diyl, cyclobutan-1,3-diyl, but-1-en-1,1-diyl, but-1-en-1,2-diyl, but-1-en-1,3-diyl, but-1-en-1,4-diyl, 2-methyl-prop-1-en-1,1-diyl, 2-methylprop-2-en-1,1-diyl, buta-1,3-dien-1,1-diyl, buta-1,3-dien-1,2-diyl, buta-1,3-dien-1,3-diyl, buta-1,3-dien-1,4-diyl, cyclobut-1-en-1,2-diyl, cyclobut-1-en-1,3-diyl, cyclobut-2-en-1,2-diyl, cyclobuta-1,3-dien-1,2-diyl, cyclobuta-1,3-dien-1,3-diyl, but-1-yn-1,3-diyl, but-1-yn-1,4-diyl, buta-1,3-diyn-1,4-diyl, etc.; and the like. Where specific levels of saturation are intended, the nomenclature alkandiyl, alkendiyl and/or alkyndiyl is used. In preferred embodiments, the alkyldiyl group is (C₁₋₈) alkyldiyl, with (C₁₋₈) being particularly preferred. Also preferred are saturated acyclic alkandiyl radicals in which the radical centers are at the terminal carbons, e.g., methandiyl; ethan-1,2-diyl; propan-1,3-diyl; butan-1,4-diyl; and the like (also referred to as alkylenos, as defined *infra*).

"Vic Alkyldiyl:" refers to a saturated or unsaturated, branched, straight-chain or cyclic hydrocarbon radical having two adjacent monovalent radical centers derived by the removal of one hydrogen atom from each of two adjacent carbon atoms of a parent alkane, alkene or alkyne. The two monovalent radical centers can form bonds with the same or different atom(s). Typical *vic* alkyldiyls include, but are not limited to *vic* ethyldiyls such as ethan-1,2-diyl, ethen-1,2-diyl; *vic* propyldiyls such as propan-1,2-diyl, cyclopropan-1,2-diyl, prop-1-en-1,2-diyl, prop-2-en-1,2-diyl, cycloprop-1-en-1,2-diyl, etc.; *vic* butyldiyls such as butan-1,2-diyl, 2-methyl-propan-1,2-diyl, cyclobutan-1,2-diyl, but-1-en-1,2-diyl, cyclobut-1-en-1,2-diyl, buta-1,3-dien-1,2-diyl, cyclobuta-1,3-dien-1,2-diyl, but-3-yn-1,2-diyl, etc.; and the like. Where specific levels of saturation are intended, the nomenclature *vic* alkandiyl, *vic* alkendiyl and/or *vic* alkyndiyl is used. In preferred embodiments, the *vic* alkyldiyl group is (C₂₋₈) *vic* alkyldiyl, with (C₂₋₃) being particularly preferred.

15

"Gem Alkyldiyl:" refers to a saturated or unsaturated, branched, straight-chain or cyclic hydrocarbon radical having one divalent radical center derived by the removal of two hydrogen atoms from a single carbon atom of a parent alkane, alkene or alkyne. The divalent radical center forms bonds with two different atoms. Typical *gem* alkyldiyls include, but are not limited to *gem* methanyldiyl; *gem* ethyldiyls such as ethan-1,1-diyl, ethen-1,1-diyl; *gem* propyldiyls such as propan-1,1-diyl, propan-2,2-diyl, cyclopropan-1,1-diyl, prop-1-en-1,1-diyl, cycloprop-2-en-1,1-diyl, prop-2-yn-1,1-diyl, etc.; butyldiyls such as butan-1,1-diyl, butan-2,2-diyl, 2-methyl-propan-1,2-diyl, cyclobutan-1,1-diyl, but-1-en-1,1-diyl, 2-methyl-prop-1-en-1,1-diyl, 2-methyl-prop-2-en-1,1-diyl, cyclobut-2-en-1,1-diyl, buta-1,3-dien-1,1-diyl, etc.; and the like. Where specific levels of saturation are intended, the nomenclature *gem* alkandiyl, *gem* alkendiyl and/or *gem* alkyndiyl is used. In preferred embodiments, the *gem* alkyldiyl group is (C₁₋₆) *gem* alkyldiyl, with (C₁₋₃) being particularly preferred.

30

"Alkyleno:" refers to a saturated or unsaturated, straight-chain or branched acyclic bivalent hydrocarbon bridge radical derived by the removal of one hydrogen atom from each of the two terminal carbon atoms of an acyclic

parent alkane, alkene or alkyne. Typical alkyleno groups include, but are not limited to, methano; ethylenos such as ethano, etheno, ethyno; propylenos such as propano, propeno, prop-1,2-dieno, propyno, etc.; butylenos such as butano, 2-methyl-propano, but-1-eno, but-2-eno, 2-methyl-prop-1-eno, 2-methanylidene-propano, but-1,3-dieno, but-1-yno, but-2-yno, but-1,3-diyno, etc.; and the like. Where specific levels of saturation are intended, the nomenclature alkano, alkeno and/or alkyno is used. In preferred embodiments, the alkyleno group is (C₁₋₈) alkyleno, with (C₁₋₃) being particularly preferred. Also preferred are straight-chain saturated alkano radicals, e.g., methano, ethano, propano, butano, and the like.

"Alkylidene:" refers to a saturated or unsaturated, branched, straight-chain or cyclic divalent hydrocarbon radical derived by removal of two hydrogen atoms from the same carbon atom of a parent alkane, alkene or alkyne. The divalent radical center forms a double bond with a single atom. Typical alkylidene radicals include, but are not limited to, methanylidene, ethylidenes such as ethanylidene, ethenylidene; propylidenes such as propan-1-ylidene, propan-2-ylidene, cyclopropan-1-ylidene, prop-1-en-1-ylidene, prop-2-en-1-ylidene, cycloprop-2-en-1-ylidene, etc.; butylidenes such as butan-1-ylidene, butan-2-ylidene, 2-methyl-propan-1-ylidene, cyclobutan-1-ylidene, but-1-en-1-ylidene, but-2-en-1-ylidene, but-3-en-1-ylidene, buta-1,3-dien-1-ylidene; cyclobut-2-en-1-ylidene, etc.; and the like. Where specific levels of saturation are intended, the nomenclature alkanylidene, alkenylidene and/or alkynylidene is used. In preferred embodiments, the alkylidene group is (C₁₋₈) alkylidene, with (C₁₋₃) being particularly preferred. Also preferred are acyclic saturated alkanylidene radicals in which the divalent radical is at a terminal carbon, e.g., methanylidene, ethan-1-ylidene, propan-1-ylidene, butan-1-ylidene, 2-methyl-propan-1-ylidene, and the like.

"Alkylidyne:" refers to a saturated or unsaturated, branched or straight-chain trivalent hydrocarbon radical derived by removal of three hydrogen atoms from the same carbon atom of a parent alkane, alkene or alkyne. The trivalent radical center forms a triple bond with a single atom. Typical alkylidyne

radicals include, but are not limited to, methanyldiyne; ethanyldiyne; propyldiynes such as propan-1-ylidyne, prop-2-en-1-ylidyne, prop-2-yn-1-ylidyne; butyldiynes such as butan-1-ylidyne, 2-methyl-propan-1-ylidyne, but-2-en-1-ylidyne, but-3-en-1-ylidyne, buta-2,3-dien-1-ylidyne, but-2-yn-1-ylidyne, but-3-yn-1-ylidyne, etc.; and the like. Where specific levels of saturation are intended, the nomenclature alkanyldiyne, alkenyldiyne and/or alkynyldiyne is used. In preferred embodiments, the alkylidyne group is (C₁₋₈) alkylidyne, with (C₁₋₃) being particularly preferred. Also preferred are saturated alkanyldiyne radicals, e.g., methanyldiyne, ethanyldiyne, propan-1-ylidyne, butan-1-ylidyne, 2-methyl-propan-1-ylidyne, and the like.

"Heteroalkyl, Heteroalkanyl, Heteroalkenyl, Heteroalkynyl, Heteroalkylidene, Heteroalkylidyne, Heteroalkyldiyl, Vic Heteralkyldiyl, Gem Heteroalkyldiyl, Heteroalkyleno and Heteroalkyldiylidene:" refer to alkyl, alkanyl, alkenyl, alkynyl, alkylidene, alkylidyne, alkyldiyl, vic alkyldiyl, gem alkyldiyl, alkyleno and alkyldiylidene radicals, respectively, in which one or more carbon atoms (and any necessary associated hydrogen atoms) are independently replaced with the same or different heteroatoms (including any necessary hydrogen or other atoms). Typical heteroatoms to replace the carbon atom(s) include, but are not limited to, N, P, O, S, Si, etc. Preferred heteroatoms are O, N and S. Thus, heteroalkyl, heteroalkanyl, heteroalkenyl, heteroalkynyl, heteroalkylidene, heteroalkylidyne, heteroalkyldiyl, vic heteroalkyldiyl, gem heteroalkyldiyl, heteroalkyleno and heteroalkyldiylidene radicals can contain one or more of the same or different heteroatomic groups, including, by way of example and not limitation, epoxy (–O–), epidioxy (–O–O–), thioether (–S–), epidthio (–SS–), epoxythio (–O–S–), epoxyimino (–O–NR'–), imino (–NR'–), biimino (–NR'–NR'–), azino (=N–N=), azo (–N=N–), azoxy (–N–O–N–), azimino (–NR'–N=N–), phosphano (–PH–), λ^4 -sulfano (–SH₂–), sulfonyl (–S(O)₂–), and the like, where each R' is independently hydrogen or (C₁–C₆) alkyl.

"Parent Aromatic Ring System:" refers to an unsaturated cyclic or polycyclic ring system having a conjugated π electron system. Specifically

included within the definition of "parent aromatic ring system" are fused ring systems in which one or more rings are aromatic and one or more rings are saturated or unsaturated, such as, for example, indane, indene, phenalene, etc. Typical parent aromatic ring systems include, but are not limited to,

5 aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene,

10 pyranthrene, rubicene, triphenylene, trinaphthalene, and the like

"Aryl:" refers to a monovalent aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to,

15 radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene,

20 picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like. In preferred embodiments, the aryl group is (C₅₋₂₀) aryl, with (C₅₋₁₀) being particularly preferred. Particularly preferred aryl groups are phenyl and naphthyl groups.

25 "Arylalkyl:" refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal carbon atom, is replaced with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl,

30 2-naphthophenylethan-1-yl and the like. Where specific alkyl moieties are intended, the nomenclature arylalkanyl, arylakenyl and/or arylalkynyl is used. [In preferred embodiments, the arylalkyl group is (C₆₋₂₆) arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C₁₋₆) and the aryl

moiety is (C₅₋₂₀). In particularly preferred embodiments the arylalkyl group is (C₆₋₁₃), e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C₁₋₃) and the aryl moiety is (C₅₋₁₀). Even more preferred arylalkyl groups are phenylalkanyls.

5

"Alkanyloxy:" refers to a saturated branched, straight-chain or cyclic monovalent hydrocarbon alcohol radical derived by the removal of the hydrogen atom from the hydroxide oxygen of the alcohol. Typical alkanyloxy groups include, but are not limited to, methanyl; ethanyloxy; propanyloxy groups such as propan-1-yloxy (CH₃CH₂CH₂O-), propan-2-yloxy ((CH₃)₂CHO-),
10 cyclopropan-1-yloxy, etc.; butanyloxy groups such as butan-1-yloxy, butan-2-yloxy, 2-methyl-propan-1-yloxy, 2-methyl-propan-2-yloxy, cyclobutan-1-yloxy, etc.; and the like. In preferred embodiments, the alkanyloxy groups are (C₁₋₈) alkanyloxy groups, with (C₁₋₃) being particularly preferred.

15

"Parent Heteroaromatic Ring System:" refers to a parent aromatic ring system in which one or more carbon atoms are each independently replaced with a heteroatom. Typical heteratoms to replace the carbon atoms include, but are not limited to, N, P, O, S, Si etc. Specifically included within the
20 definition of "parent heteroaromatic ring systems" are fused ring systems in which one or more rings are aromatic and one or more rings are saturated or unsaturated, such as, for example, arsindeole, chromane, chromene, indole, indoline, xanthene, etc. Typical parent heteroaromatic ring systems include, but are not limited to, arsindeole, carbazole, β -carboline, chromane, chromene,
25 cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline,
30 quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like.

"Heteroaryl:" refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system. Typical heteroaryl groups include, but are not limited to, radicals derived from acridine, arsindole, carbazole, β -carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. In preferred embodiments, the heteroaryl group is a 5–20 membered heteroaryl, with 5–10 membered heteroaryl being particularly preferred. Specific preferred heteroaryls for the present invention are quinoline, isoquinoline, pyridine, pyrimidine, furan, thiophene and imidazole.

"Substituted:" refers to a radical in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s). Typical substituents include, but are not limited to, $-X$, $-R$, $-O^{\cdot}$, $=O$, $-OR$, $-O-OR$, $-SR$, $-S^{\cdot}$, $=S$, $-NRR$, $=NR$, $-CX_3$, $-CN$, $-OCN$, $-SCN$, $-NCO$, $-NCS$, $-NO$, $-NO_2$, $=N_2$, $-N_3$, $-NHOH$, $-S(O)_2O^{\cdot}$, $-S(O)_2OH$, $-S(O)_2R$, $-P(O)(O^{\cdot})_2$, $-P(O)(OH)_2$, $-C(O)R$, $-C(O)X$, $-C(S)R$, $-C(S)X$, $-C(O)OR$, $-C(O)O^{\cdot}$, $-C(S)OR$, $-C(O)SR$, $-C(S)SR$, $-C(O)NRR$, $-C(S)NRR$ and $-C(NR)NRR$, where each X is independently a halogen (preferably $-F$, $-Cl$ or $-Br$) and each R is independently $-H$, alkyl, alkanyl, alkenyl, alkynyl, alkylidene, alkylidyne, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl or heteroaryl-heteroalkyl, as defined herein. Preferred substituents include hydroxy, halogen, C_{1-8} alkyl, C_{1-8} alkanyloxy, fluorinated alkanyloxy, fluorinated alkyl, C_{1-8} alkylthio, C_{3-8} cycloalkyl, C_{3-8} cycloalkanyloxy, nitro, amino, C_{1-8} alkylamino, C_{1-8} dialkylamino, C_{3-8} cycloalkylamino, cyano, carboxy, C_{1-7} alkanyloxycarbonyl, C_{1-7} alkylcarbonyloxy, formyl, carbamoyl, phenyl, aroyl,

carbamoyl, amidino, (C₁₋₈alkylamino)carbonyl, (arylamino)carbonyl and aryl(C₁₋₈alkyl)carbonyl.

"Aroyl" refers to arylacyl substituents.

5


"Acyl" refers to alkylcarbonyl substituents.

With reference to substituents, the term "independently" means that when more than one of such substituent is possible, such substituents may be the same or different from each other.

10


Throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment. Thus, for example, a "phenylC₁₋₆alkanylaminocarbonylC₁₋₆alkyl" substituent refers to a group of the formula

15



20

The present invention is directed to compositions comprising a compound of Formula (I):



Formula (I)

wherein R₁ independently may be absent or an optionally substituted substituent selected from alkyl, heteroalkyl, aryl (preferably 5–10 membered aryl), arylalkyl, halogen, nitro, amino, cyano, carboxy, carbamoyl, aroyl, amidino, and acyl; n is an integer from 1 to 3; m is an integer from 0 to 3; R₂ may be absent or an optionally substituted substituent selected from alkyl,

25

heteroalkyl, aryl (preferably 5–10 membered aryl), heteroaryl (preferably 5–10 membered heteroaryl), alkylidenyl, heteroalkylidenyl, alkylidynyl, heteroalkylidynyl, arylalkyl, halogen, nitro, amino, and cyano; L is a direct bond, alkylidyl or heteroalkylidyl; R₃ is aryl (preferably 5–10 membered aryl) or
 5 heteroaryl (preferably 5–10 membered heteroaryl); R₄ and R₅ are hydrogen, alkyl, or heteroalkyl; X is O or S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

10 In particular, the present invention is directed to compounds of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen,
 15 fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen,
 20 fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro,
 25 amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;

n is an integer from 1 to 3;

m is an integer from 0 to 3;

R₂ is independently selected from the group consisting of hydrogen;
 30 hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; ; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈alkanyloxy, fluorinated alkanyl, cyano,

- nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino,
- 5 C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen
- 10 wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of phenyl optionally substituted
- 15 with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated
- 20 alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or
- 25 imidazolyl;
- R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- X is selected from the group consisting of O and S; and
- enantiomers, diastereomers, tautomers, solvates, and pharmaceutically
- 30 acceptable salts thereof.

Preferred embodiments of the present invention are those in which: (1)
R₁ is a substituent independently selected from the group consisting of

- hydrogen, hydroxy, fluoro, chloro, bromo, and C₁₋₈alkanyloxy; (2) R₁ is a substituent independently selected from the group consisting of fluoro, chloro, bromo, C₁₋₈alkanyloxy, (3) R₂ is independently selected from the group consisting of hydrogen, C₂₋₈alkenyl, C₁₋₈alkylidenyl, C₁₋₈alkylidynyl,
- 5 C₃₋₈cycloalkanyl, phenyl (optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl), naphthyl (optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo,
- 10 hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl), and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein the heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; (4) L is a direct bond or C₁₋₈alkandiyl; (5) R₃ is selected from the group consisting of
- 15 naphthyl substituted with hydroxyl; quinolinyl and isoquinolinyl; and (6) any combination of (1) to (5) preceding. Thus, preferred embodiments of the present invention are as described below.

- An embodiment of the present invention is directed to compositions
- 20 comprising a compound of Formula (I) wherein:
- R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy;
- n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- 25 R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano,
- 30 nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino,

C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents
5 independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

10 R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the
15 group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl,
20 isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers,
25 diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

30 R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted

with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;

n is an integer from 1 to 3;

m is an integer from 0 to 3;

R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈alkanyloxy, fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈alkanyloxy, fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈alkanylamino, C₁₋₈alkanylamino and cyano; and

heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or
 5 imidazolyl;
 R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts
 10 thereof.

Still another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting of
 15 hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy;
 20 fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl;
 25 carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;

n is an integer from 1 to 3;

30 m is an integer from 0 to 3;

R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the

group consisting of fluoro, chloro, bromo, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy and fluorinated
5 alkanyl; pyridyl; pyrimidyl; furyl; thienyl and imidazolyl.

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting
10 of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and
15 heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

20 R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

25

Furthermore, another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more
30 substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy;

- fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino;
- 5 cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- 10 n is an integer from 1 to 3;
m is an integer from 0 to 3;
R₂ is independently selected from the group consisting of C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting
- 15 of fluoro, chloro, bromo, and fluorinated alkanyl.
L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;
R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting
- 20 of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and
- 25 heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinoliny, quinoliny-N-oxide, isoquinoliny, isoquinoliny-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;
- 30 R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

5 An embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

R_1 is a substituent independently selected from the group consisting of fluoro; chloro; C_{1-8} alkanyloxy;

 n is an integer from 1 to 3;

10 m is an integer from 0 to 3;

R_2 is independently selected from the group consisting of hydrogen; hydroxy; C_{1-8} alkanyl; C_{2-8} alkenyl; C_{1-8} alkylidenyl; C_{1-8} alkylidynyl; fluoro; chloro; C_{3-8} cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy,

15 C_{1-8} alkanyl, C_{1-8} alkanyloxy, phenyl(C_{1-8})alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C_{1-8} alkanylamino, and C_{1-8} dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy, phenyl(C_{1-8})alkanyloxy, fluorinated alkanyl, cyano, nitro, amino,

20 C_{1-8} alkanylamino, and C_{1-8} dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-6} alkanyl and halogen
25 wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

 L is a direct bond, C_{1-8} alkandiyl, C_{2-8} alkendiyl, C_{2-8} alkyndiyl, or C_{3-8} cycloalkandiyl;

R_3 is selected from the group consisting of phenyl optionally
30 substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl, halogen, C_{1-8} alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C_{1-8})alkanylamino, C_{1-8} alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently

selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of

5 C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

10 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

15

Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or

20 more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or

25 more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with

30 one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;

n is 1;

- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents
- 5 independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy,
- 10 phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents
- 15 independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;
- 20 R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently
- 25 selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is
- 30 quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;
- R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and
 5 acceptable salts thereof.

Still yet another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting
 10 of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated
 15 alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with
 20 one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;

n is an integer from 1 to 3;

25 m is an integer from 0 to 1;

R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy,
 30 C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy,

phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and
5 nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or
10 C₃₋₈cycloalkandiyl;

R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano;
15 naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of
20 C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

25 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

30

Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

- R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl;
- 5 C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino;
- 10 $(C_{1-8}$ alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C_{1-8} alkanyl)carbonyl;
- n is an integer from 1 to 3;
- m is 1;
- R_2 is independently selected from the group consisting of hydrogen; hydroxy; C_{1-8} alkanyl; C_{2-8} alkenyl; C_{1-8} alkylidenyl; C_{1-8} alkylidynyl; fluoro; chloro;
- 20 C_{3-8} cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy, phenyl(C_{1-8} alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C_{1-8} alkanylamino, and C_{1-8} dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy,
- 25 phenyl(C_{1-8} alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C_{1-8} alkanylamino, and C_{1-8} dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy, fluorinated alkanyl, cyano and
- 30 nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-6} alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl;

- C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;
 C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;
 C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with
 one to three substituents independently selected from the group consisting of
 5 halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino;
 (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
 n is an integer from 1 to 3;
 m is an integer from 0 to 3;
 R₂ is independently selected from the group consisting of hydrogen;
 10 hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro;
 C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents
 independently selected from the group consisting of halogen, hydroxy,
 C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano,
 nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally
 15 substituted with one to three substituents independently selected from the
 group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy,
 phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino,
 C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with
 one to three substituents independently selected from the group consisting of
 20 halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and
 nitro; and heteroaryl optionally substituted with one to three substituents
 independently selected from the group consisting of C₁₋₆alkanyl and halogen
 wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl;
 pyrrolidino; and piperidino;
 25 L is a direct bond or C₁₋₈alkandiyl;
 R₃ is selected from the group consisting of phenyl optionally
 substituted with one to three substituents independently selected from the
 group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated
 alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano;
 30 naphthyl optionally substituted with one to three substituents independently
 selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy,
 hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
 C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to

three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

5 R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

 X is selected from the group consisting of O and S; and
10 enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

Yet another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

15 R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the
20 group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;
25 C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;

30 n is an integer from 1 to 3;

 m is an integer from 0 to 3;

 R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro;

- C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- 15 L is a direct bond;
- R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano;
- 20 naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of
- 25 C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;
- R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- 30 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

5 Still yet another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of

10 halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of

15 halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of

20 halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;

n is an integer from 1 to 3;

m is an integer from 0 to 3;

R₂ is independently selected from the group consisting of hydrogen;

25 hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally

30 substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with

one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen
5 wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

R₃ is selected from the group consisting of phenyl substituted with
10 one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, fluoro, chloro, bromo, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, fluoro, chloro, bromo, C₁₋₈alkanyloxy, hydroxy,
15 fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, fluoro and chloro, wherein said heteroaryl is quinoliny-N-oxide, isoquinoliny, isoquinoliny-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or
20 imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

25 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

Furthermore, another embodiment of the present invention is directed to
30 compositions comprising a compound of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of

- halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or
- 5 more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with
- 10 one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- 15 R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano,
- 20 nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with
- 25 one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl;
- 30 pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

- R_3 is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyloxy and hydroxy; naphthyl substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyloxy and hydroxy; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl and chloro wherein said heteroaryl is quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl and pyridyl-N-oxide;
- R_4 is selected from the group consisting of hydrogen and C_{1-8} alkanyl;
- R_5 is selected from the group consisting of hydrogen and C_{1-8} alkanyl;
- X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein

- R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; $(C_{1-8}$ alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C_{1-8} alkanyl)carbonyl;

- n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro;
- 5 C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the
- 10 group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and
- 15 nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or
- 20 C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro, quinolinyl-N-oxide, isoquinolinyl optionally substituted with one or more substituents selected from
- 25 the group consisting of methyl and chloro and isoquinolinyl-N-oxide;
- R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- 30 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

- R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally independently substituted
- 5 with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio
- 10 optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; formyl; carbamoyl; phenyl
- 15 optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C_{1-8} alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C_{1-8} alkanyl)carbonyl;
- n is an integer from 1 to 3;
- 20 m is an integer from 0 to 3;
- R_2 is independently selected from the group consisting of hydrogen; hydroxy; C_{1-8} alkanyl; C_{2-8} alkenyl; C_{1-8} alkylidenyl; C_{1-8} alkylidynyl; fluoro; chloro; C_{3-8} cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy,
- 25 C_{1-8} alkanyl, C_{1-8} alkanyloxy, phenyl(C_{1-8} alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C_{1-8} alkanylamino, and C_{1-8} dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy, phenyl(C_{1-8} alkanyloxy, fluorinated alkanyl, cyano, nitro, amino,
- 30 C_{1-8} alkanylamino, and C_{1-8} dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents

independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or
5 C₃₋₈cycloalkandiyl;

R₃ is 2-hydroxynaphth-8-yl, isoquinolin-5-yl and isoquinoliny-5-yl-N-oxide;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

10 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

15

Yet another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or
20 more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one
25 or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with
30 one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;

n is an integer from 1 to 3;

m is an integer from 0 to 3;

R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents
5 independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy,
10 phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents
15 independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

20 R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently
25 selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is
30 quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is hydrogen;

R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and
 5 acceptable salts thereof.

Still yet another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting
 10 of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated
 15 alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;

n is an integer from 1 to 3;

25 m is an integer from 0 to 3;

R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy,
 30 C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy,

phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and
5 nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or
10 C₃₋₈cycloalkandiyl;

R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano;
15 naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of
20 C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

25 R₅ is hydrogen;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.


30 Furthermore, another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:

R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally substituted with one or

- more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

- R_3 is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl, halogen, C_{1-8} alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C_{1-8})alkanylamino, C_{1-8} alkanylamino and cyano;
- 5 naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-8} alkanyl, halogen, C_{1-8} alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C_{1-8})alkanylamino, C_{1-8} alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of
- 10 C_{1-8} alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;
- R_4 is selected from the group consisting of hydrogen and C_{1-8} alkanyl;
- 15 R_5 is selected from the group consisting of hydrogen and C_{1-8} alkanyl;
- X is O; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

- 20 Another embodiment of the present invention is directed to compositions comprising a compound of Formula (Ia):



Formula (Ia)

the compound selected from the group consisting of:

- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is 3-Pyridinyl, m is 1,
- 25 L is $-CH_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is H, m is 0, L is $-CH_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 3-Pyridinyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-(Methoxymethyleneoxy)Ph, and X is S;
- 5 a compound of formula (Ia) wherein R_1 is H, R_2 is 3-Pyridinyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is 3-Pyridinyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is $-\text{CH}=\text{CH}_2$, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-(Methoxymethyleneoxy)Ph, and X is S;
- 10 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is 4-Imidazolyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-methylenedioxy)Ph, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-diOMe)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (4-*t*Bu)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (4-Cl)Ph, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (3,4-diOMe)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-methylenedioxy)Ph, and X is S;
- 25 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-diOMe)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (4-*t*Bu)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (4-Cl)Ph, and X is S;
- 30 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (3,4-diOMe)Ph, and X is S;

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (3-OMe-4-OH)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH=CH-(), R_3 is (3-OMe-4-OH)Ph, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (3-OMe-4-(Methoxymethyleneoxy)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (4-N(Me)(C₅H₁₁))Ph, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (4-[N(Me)(cyclohexyl)])Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (3,4-diOMe)Ph, and X is S;
- 15 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (4-CF₃)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (3,4-diCl)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂CH₂-, R_3 is (3,4-diCl)Ph, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (4-CF₃)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (3,4-diCl)Ph, and X is S;
- 25 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂CH₂-, R_3 is (3,4-diCl)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-quinoliny, and X is O;
- 30 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 8-(2-naphtholyl), and X is O;

a compound of formula (Ia) wherein R_1 is H, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

5 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-Br, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

10 a compound of formula (Ia) wherein R_1 is 6,7-diOMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 7-Cl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 5-Cl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

15 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (3-Cl)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

20 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is 3-Pyridinyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (3-Cl)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is 3-Pyridinyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

25 a compound of formula (Ia) wherein R_1 is 6,7-diOMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-Cl)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

30 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-Cl)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-Cl)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-CF₃)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (3-CF₃)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-CF₃)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OH, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is H, R_2 is -CH=CH₂, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-Br, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is -CH₂-, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 7-Cl, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 8-Cl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-CN)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 25 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-Br)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is CN, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6,7-diF, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 30 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 8-(2-naphtholyl), and X is O;

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is $-\text{CH}=\text{CH}_2$, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is $-\text{CH}=\text{CH}_2$, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Cyclopropyl, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-Benzoyloxy)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-Pyridiny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is 2-Thienyl, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2,6-diF)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is $-\text{CH}_2=\text{CH}_2$, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 7-F, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- 25 a compound of formula (Ia) wherein R_1 is 5-F, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- 30 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is H, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;

- a compound of formula (Ia) wherein R_1 is H, R_2 is Cyclopropyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 3-thienyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- 5 a compound of formula (Ia) wherein R_1 is H, R_2 is 2-thienyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 3-furyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 2-furyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- 10 a compound of formula (Ia) wherein R_1 is H, R_2 is 4-pyridinyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 3-pyridinyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- 15 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}(\text{Me})-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}(\text{Me})\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- 20 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (3-OMe-4- $\text{OCH}_2\text{CH}_2\text{NH}_2$)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}(\text{Me})-$, R_3 is (3-OMe-4- $\text{OCH}_2\text{CH}_2\text{NH}_2$)Ph, and X is S;
- 25 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}(\text{Me})\text{CH}_2-$, R_3 is (3-OMe-4- $\text{OCH}_2\text{CH}_2\text{NH}_2$)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- 30 a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;

- a compound of formula (Ia) wherein R_1 is 6,7-diF, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 7-Cl, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- 5 a compound of formula (Ia) wherein R_1 is 5-Cl, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 8-Cl, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-OMe)Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- 10 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (3-OMe)Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-OMe)Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- 15 a compound of formula (Ia) wherein R_1 is 6,7-diOMe, R_2 is $-\text{CH}_2=\text{CH}_2$, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is cyclopropyl, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-*t*-Bu, R_2 is (4-*t*-Bu)Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- 20 a compound of formula (Ia) wherein R_1 is 6-CF₃, R_2 is (4-CF₃)Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 3-pyridinyl, and X is S;
- 25 a compound of formula (Ia) wherein R_1 is 8-F, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 2-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is 3-pyridinyl, and X is S;
- 30 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is 2-pyridinyl, and X is S;

- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (2-OMe-3-OH)-5-thienyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 6,7-diF, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is 8-Cl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6,7-diOMe, R_2 is $-\text{CH}_2=\text{CH}_2$,
10 m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-*t*-Bu, R_2 is (4-*t*-Bu)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-CF₃, R_2 is (4-CF₃)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is (4-Cl)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is (3-Cl)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is (2-Cl)Ph, m is 1, L
20 is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is (4-CF₃)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is (3-CF₃)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 25 a compound of formula (Ia) wherein R_1 is H, R_2 is (2-CF₃)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is (3-OMe-4-OH)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is (3-OH-4-OMe)Ph, m
30 is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe-7-OH, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OH-7-OMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-Me, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

5 a compound of formula (Ia) wherein R_1 is 6-C(Me₂)CH₂Me, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-NO₂, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OSO₃Me, R_2 is Ph, m is 1,
10 L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-NHSO₂Ph, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-CO₂H, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

15 a compound of formula (Ia) wherein R_1 is 6-C(O)NH₂, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-C(O)NMe₂, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-C(O)NHMe, R_2 is Ph, m is
20 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-CO₂Ph, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-cyclohexyl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

25 a compound of formula (Ia) wherein R_1 is 6-Ph, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-NHC(O)(CH₂)₄-CH=CH-CH(Me)₂, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

30 a compound of formula (Ia) wherein R_1 is H, R_2 is 2-pyridinyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is H, R_2 is 3-pyridinyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

- a compound of formula (Ia) wherein R_1 is H, R_2 is 4-pyridinyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 3-thienyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is H, R_2 is 3-furyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 2-furyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-hydroxynaphth-8-yl, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 1-hydroxynaphth-8-yl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 4-hydroxynaphth-8-yl, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-hydroxynaphth-8-yl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-chloro-2-hydroxynaphth-8-yl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 2,3-dihydroxynaphth-8-yl, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-cinnolinyl, and X is O;
- 25 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-Me-5-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 4-(1,8-naphthyridinyl), and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-quinazolinyl, and X is O;
- 30 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 2-OH-5-quinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-OH-5-quinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-F-5-quinolinyl, and X is O;

5 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-Cl-5-quinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 2-OH-3-Cl-5-quinolinyl, and X is O;

10 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is $-\text{CH}_2=\text{CH}_2$, m is 1, L is a direct bond, R_3 is 5-quinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is $-\text{CH}_2\text{CH}_3$, m is 1, L is a direct bond, R_3 is 5-quinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 8-Cl-5-quinolinyl, and X is O;

15 a compound of formula (Ia) wherein R_1 is H, R_2 is 2-naphthyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 1,3-diMe-5-isoquinolinyl, and X is O;

20 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 8-Cl-5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 1,3-diMe-8-Cl-5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 5-isoquinolinyl, and X is O;

25 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-quinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-quinolinyl, and X is O;

30 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-quinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OH-7-OMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-quinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6,7-diOH, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-quinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-OMe-7-OH, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-quinolinyl, and X is O;

5 a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-quinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-Cl-5-isoquinolinyl, and X is O;

10 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-Me-5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-Me-5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-Br, R₂ is Ph, m is 1, L is a direct bond, R₃ is 8-isoquinolinyl, and X is O;

15 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 2-furyl, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

20 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 4-Cl-5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl-N-oxide, and X is O;

a compound of formula (Ia) wherein R₁ is 6-Cl, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

25 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 3-furanyl, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-OCH₃, R₂ is 3-thienyl, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

30 a compound of formula (Ia) wherein R₁ is 6-OCH₃, R₂ is 2,4 di-F Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-OCH₃, R₂ is 2,4 di-F Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-OCH₃, R₂ is Ph, m is 1, L is

- a direct bond, R₃ is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-Cl, R₂ is Ph, m is 1, L is a
- 5 direct bond, R₃ is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl-N-oxide, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 4-Cl- 5-isoquinolinyl, and X is O;
- 10 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 4-Cl-5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-methyl-5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a
- 15 direct bond, R₃ is 1-methyl-5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-Cl-5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-Cl, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl-N-oxide, and X is O;
- 20 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 4-CF₃ Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1,3-diCl- 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a
- 25 direct bond, R₃ is 1,3-diCl-5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 8-Cl-5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-piperidinyl-5-isoquinolinyl, and X is O;
- 30 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-OCH₃-5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-F- 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 1-N,N-dimethyl-5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is nil, m is nil, R_3 is 1-CH₃-5-isoquinolinyl, and X is O;

5 a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is nil, m is nil, R_3 is 1-Cl-5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is 3-CF₃ Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

10 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is 3-CF₃ Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl-N-oxide, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is 3-CF₃ Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl-N-oxide, and X is O;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is spiro-2-indanyl, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

15 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is 4-Cl,3-CF₃ Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O; and

a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 1-CH₃-5-isoquinolinyl, and X is O.

20

Preferred compounds of Formula (Ia) are selected from the group consisting of:

25 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (3-OMe-4-OH)Ph, and X is S;

a compound of formula (Ia) wherein R_1 is H, R_2 is 3-Pyridinyl, m is 1, L is -CH₂-, R_3 is (3-OMe-4-OH)Ph, and X is S;

a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (3-OMe-4-OH)Ph, and X is O;

30 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (3-OMe-4-OH)Ph, and X is S;

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is -CH₂-, R_3 is (3,4-diOMe)Ph, and X is S;

a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is Ph, m is 1, L is a direct bond, R₃ is 8-(2-naphtholyl), and X is O;

5 a compound of formula (Ia) wherein R₁ is H, R₂ is H, m is 0, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-F, R₂ is H, m is 0, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

10 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-Br, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6,7-diOMe, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

15 a compound of formula (Ia) wherein R₁ is 7-Cl, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 5-Cl, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

20 a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (3-Cl)Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6,7-diOMe, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

25 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (2-Cl)Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-Cl)Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

30 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is H, m is 0, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (2-CF₃)Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (3-CF₃)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-CF₃)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is H, R_2 is -CH=CH₂, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-Br, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is -CH₂-, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 7-Cl, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 8-Cl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-CN)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-Br)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 6,7-diF, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is -CH=CH₂, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 25 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is -CH=CH₂, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 30 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is 2-Thienyl, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O.

More preferred compounds of Formula (Ia) are selected from the group consisting of:

- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is 6-Br, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 5-Cl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 6-Br, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 7-Cl, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6,7-diF, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is $-\text{CH}=\text{CH}_2$, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O; and
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is 2-Thienyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O.

25

Still other more preferred compounds of Formula (Ia) are selected from the group consisting of:

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- 30 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (3-Cl)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-Cl)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

- a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (2-CF₃)Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (3-CF₃)Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
- 5 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-CF₃)Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-Br)Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-OMe)Ph, m is 10 is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O.

The compounds of the present invention may also be present in the form of pharmaceutically acceptable salts. For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts" (*Ref. International J. Pharm.*, **1986**, 33, 201-217; *J. Pharm.Sci.*, **1997** (Jan), 66, 1, 1). Other salts well known to those in the art may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Representative organic or inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydriodic, perchloric, 15 sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, *p*-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. Representative organic or inorganic bases 20 include, but are not limited to, basic or cationic salts such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium and zinc.

The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional 30 derivatives of the compounds which are readily convertible *in vivo* into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the

various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound *in vivo* after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are
5 described, for example, in "Design of Prodrugs", ed. H. Bundgaard; Elsevier, 1985.

Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the
10 compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention.
15 In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.

Where the processes for the preparation of the compounds according to
20 the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers
25 by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic
30 separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.

During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in

- 5 Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

- 10 Even though the compounds of the present invention (including their pharmaceutically acceptable salts and pharmaceutically acceptable solvates) can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent selected with regard to the intended route of administration and standard pharmaceutical or veterinary
15 practice. Thus, the present invention is directed to pharmaceutical and veterinary compositions comprising compounds of Formula (I) and one or more pharmaceutically acceptable carriers, excipients or diluents.

- By way of example, in the pharmaceutical and veterinary compositions
20 of the present invention, the compounds of the present invention may be admixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilising agent(s).

- Tablets or capsules of the compounds may be administered singly or
25 two or more at a time, as appropriate. It is also possible to administer the compounds in sustained release formulations.

- Alternatively, the compounds of the general Formula (I) can be administered by inhalation or in the form of a suppository or pessary, or they
30 may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder. An alternative means of transdermal administration is by use of a skin patch. For example, they can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin. They can

also be incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilisers and preservatives as may be required.

- 5 For some applications, preferably the compositions are administered orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or coloring agents.
- 10 The compositions (as well as the compounds alone) can also be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. In this case, the compositions will comprise a suitable carrier or diluent.
- 15 For parenteral administration, the compositions are best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood.
- 20 For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
- 25 By way of further example, pharmaceutical and veterinary compositions containing one or more of the compounds of the invention described herein as the active ingredient can be prepared by intimately mixing the compound or compounds with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending upon the desired route of administration (e.g., oral,
- 30 parenteral). Thus for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like; for solid oral preparations, such as powders, capsules and tablets, suitable

carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Solid oral preparations may also be coated with substances such as sugars or be enteric-coated so as to modulate the major site of absorption. For parenteral administration, the

5 carrier will usually consist of sterile water and other ingredients may be added to increase solubility or preservation. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.

Advantageously, compounds of the present invention may be

10 administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those skilled in that art. To be administered in the form of a

15 transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

A therapeutically effective amount for use of the instant compounds or a pharmaceutical composition thereof comprises a dose range of from about

20 0.001 mg to about 1,000 mg, in particular from about 0.1 mg to about 500 mg or, more particularly from about 1 mg to about 250 mg of active ingredient per day for an average (70 kg) human.

For oral administration, a pharmaceutical composition is preferably

25 provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated.

It is also apparent to one skilled in the art that the therapeutically

30 effective dose for active compounds of the invention or a pharmaceutical composition thereof will vary according to the desired effect. Therefore, optimal dosages to be administered may be readily determined and will vary with the particular compound used, the mode of administration, the strength of the

preparation, and the advancement of the disease condition. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an appropriate therapeutic level. The above dosages are thus exemplary of
5 the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

Compounds of this invention may be administered in any of the foregoing
10 compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of the compounds of the invention as vanilloid receptor modulators is required for a subject in need thereof.

The invention also provides a pharmaceutical or veterinary pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical and veterinary compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of
15 pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
20

As modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating or preventing a disease or
25 condition in a mammal which disease or condition is affected by the modulation of one or more vanilloid receptors. Such methods comprises administering to a mammal in need of such treatment or prevention a therapeutically effective amount of a compound, salt or solvate of Formula (I). In particular, the compounds of Formula (I) are useful for in methods for preventing or treating a
30 chronic- or acute-pain causing diseases or conditions and pulmonary dysfunction, and more particularly, in treating diseases or conditions that cause inflammatory pain, burning pain, itch or urinary incontinence, and chronic obstructive pulmonary disease.

By way of example only, the compounds of Formula (I) are useful for treating diseases and conditions selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, inflammatory inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstruation, cancer, and trauma.

While the present invention comprises compositions comprising one or more of the compounds of Formula (I), the present invention also comprises compositions comprising intermediates used in the manufacture of compounds of Formula (I).

GENERAL SYNTHETIC METHODS

Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated in the schemes that follows. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical
5 reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.


The ureas of formula (I) that comprise this invention are synthesized
10 using several distinct chemical methods. The general transformations for constructing β -aminotetralin-derived ureas involve:

Preparation of suitably substituted β -aminotetralin, which is described in the general schemes below. Tetralone starting materials were either
15 purchased from commercial sources or were prepared using the method reported by Sims (Sims, J. J. et. al. *Tetrahedron Lett.* **1971**, 951). Specifically, substituted phenylacetic acids were separately reacted with ethylene gas and a Lewis Acid such as aluminum trichloride to afford the desired corresponding β -tetralone.

20 An appropriately substituted β -tetralone (II) is reacted with an aryl or heteroaryl aldehyde in the presence of a base such as piperidine, in an inert halohydrocarbon, ethereal or hydrocarbon solvent, such as benzene, from ambient temperature to reflux, to afford the corresponding α -benzylidenyl- β -tetralone or α -heteroarylmethylidenyl- β -tetralone (III). The β -tetralone (III) is
25 dissolved in an inert hydrocarbon, ethereal, ester or alcohol solvent, such as methanol, and reacted with hydrogen gas at a pressure from ambient pressure to 100 p.s.i. in the presence of a suitable catalyst such as palladium on carbon. The reaction is performed at a temperature from ambient temperature to
30 reflux, to yield the desired α -substituted- β -tetralone (IV) (Scheme 1).

- An alternative method for the preparation of α -substituted- β -tetralones (IV) involves the reaction of an appropriately substituted β -tetralone (II) with a base such as pyrrolidine in an inert halohydrocarbon solvent such as dichloromethane or hydrocarbon solvent such as benzene, under Dean-Stark
- 5 conditions (removal of water) or in an alcohol solvent such as methanol, from ambient temperature to reflux, to afford enamine (V). Alkylation of enamine (V) is accomplished by reaction with a benzylic, heterocyclicalkanyl or an allylic halide in an inert solvent such as acetonitrile, at a temperature from ambient temperature to reflux, to afford the α -substituted- β -iminium salt (VI).
- 10 Hydrolysis of the salt (VI) to produce the desired α -substituted- β -tetralone product (IV) is accomplished by reaction of (VI) with water and an inorganic or organic acid such as hydrochloric or glacial acetic acid in an inert hydrocarbon, ethereal, alcohol or halohydrocarbon solvent, or a mixture thereof, such as methanol and dichloromethane (Scheme 1).


15

wherein $m = 1-3$

Scheme 1


- 20 The α -substituted- β -tetralones (IV) are converted to the corresponding aminotetralins via reaction with an ammonium salt such as ammonium acetate

- in the presence of a reducing agent such as sodium cyanoborohydride, for example, in an inert halohydrocarbon, hydrocarbon, ethereal or alcohol solvent such as methanol to produce the *cis*-aminotetralin (VII). In some cases, the *trans*-aminotetralin (VIII) is also formed as a minor product; both sets of
- 5 diastereomers are part of this invention. The aminotetralins (VII) can also be isolated as acid addition salts by treatment with an organic or an inorganic acid, such as trifluoroacetic acid or hydrochloric acid, for example (Scheme 2).



Scheme 2

- Compounds in which $m = 0$ are prepared from an appropriately substituted aminotetralin (VII; $m = 0$) starting from 1-tetralones using the synthetic sequence shown in Scheme 2a.
- 15




Scheme 2a

Aminotetralin (VII) can be used in subsequent reactions as the corresponding free base or as an acid addition salt. The use of acid addition

salts requires an additive, such as an organic base like triethylamine or an inorganic base such as hydroxide, to neutralize the acid and liberate the reactive nucleophilic amine center. This common practice is well known to those skilled in the art.

5

Aminotetralin VII is reacted with isocyanate or isothiocyanate, in an appropriate inert solvent, with or without an added base, to form ureas (IX) or thioureas (X), shown in Scheme 3.




10

Scheme 3

In addition to isocyanates and isothiocyanates, other carbamylating or thiocarbamylating agents may be used and this is well known to those skilled in the art. Thus an appropriate amine, such as an aminoisoquinoline, aminonaphthol or aminoquinoline, is reacted with a chloroformate, such as phenyl chloroformate in an inert solvent, with or without added base, to afford the corresponding phenylcarbamates. Separately these carbamates are reacted with aminotetralin (VII) in a polar solvent such as dimethylsulfoxide, with or without added base, from room temperature to approximately 150 C, to produce the aminotetralin-derived ureas (IX) (Scheme 4).

15

20




Scheme 4

- 5 The use of chlorothionoformates in the scheme above produces the analogous aminotetralin-derived thioureas (X).


Isocyanates and isothiocyanates are also prepared by reacting an amine with phosgene or thiophosgene in the presence of a base.

- 10 Benzylamines such as 4-alkanyloxy-3-methoxybenzylamine is reacted with thiophosgene or a thiophosgene equivalent, in the presence of a base, such as an organic amine, to produce the corresponding thiocyanate. Subsequent reaction with aminotetralin (VII) produces the corresponding aminotetralin-derived homovanillic thioureas (Scheme 5). Protecting group manipulations
- 15 may be used to mask and subsequently liberate the phenolic OH group and this practice is well known to those skilled in the art.



Scheme 5

- 5 The use of (heteroaryl)alkanylamines, such as pyridylmethanamine, produces the corresponding aminotetralin-derived ureas in which $\text{R}_3 =$ heteroaryl (Scheme 6). Thiocarbamylation with aminotetralin, as described above, gives the analogous thioureas.




Scheme 6

- 15 Aminotetralin-derived ureas and thioureas with linking groups (L) of varying length are produced via homologation of aryl- or heteroaryl-carboxaldehydes or carboxylic acids. This practice is well known in the literature and encompasses a wide variety of chemical transformations, several of which are described below to illustrate the strategy but are not intended to be inclusive.

20

Isoquinoline is reacted with N-(hydroxymethyl)trifluoroacetamide in acid followed by reduction to afford isoquinolin-5-yl-methanamine. Carbamylation


using aminotetralin as described above, produces aminotetralin-derived ureas in which L = CH₂ (methylene) (Scheme 7).



5

Scheme 7

Aminonaphthalene is subjected to a Sandmeyer reaction, namely diazotization followed by reaction with copper cyanide at high temperature to produce the cyanonaphthalene. Reduction affords naphthalen-2-yl-
 10 methylamine which is subjected to carbamylation using aminotetralin (VII), as described above, to produce aminotetralin-derived urea in which L = CH₂ (methylene) (Scheme 8).




15

Scheme 8


Reaction of aryl- and heteroaryl-carboxaldehydes with toluenesulfonyl methylisocyanide in the presence of base, with subsequent hydrolysis affords the corresponding homologated nitrile. Reduction produces the homologated

amine which is subjected to carbamylation with aminotetralin as described above to yield aminotetralin-derived ureas in which $L = \text{CH}_2\text{CH}_2$ (Scheme 9).



Scheme 9

Heteroaryl- and aryl-carboxaldehydes are modified using Wittig conditions to give the α,β -unsaturated nitrile which is reduced to the amine and subsequent carbamylated as described above to yield aminotetralin-derived ureas in which $L = \text{CH}_2\text{CH}_2\text{CH}_2$ (Scheme 10).



Scheme 10

Homologation of heteroaryl- and aryl-carboxylic acids is also accomplished using chemistry known as the Arndt-Eistert synthesis, a

procedure that converts carboxylic acids to the next higher homolog using a three step synthesis. In the first transformation, the carboxylic acid starting material is converted to its acyl chloride, using thionyl chloride, oxalyl chloride or another appropriate chlorinating agent. In the second step, the acyl chloride
5 is converted to a diazoketone via reaction with diazomethane or a suitable equivalent. In the final transformation, the diazoketone is oxidized to the homologous acid using an oxidant such as silver oxide. The carboxylic acid group is then converted to an isocyanate through the intermediacy of the acyl azide (Curtius rearrangement) which is carried on to aminotetralin-derived
10 ureas and thioureas using the chemistry described above. Alternatively, the carboxylic acid is reacted with hydrazoic acid (or equivalent) under acid catalysis followed by thermal decomposition to the amine (Schmidt reaction), which is carried on to aminotetralin-derived ureas and thioureas using the chemistry described above.

15

This chemistry and related variations are well known to those skilled in the art.

Protecting group manipulations may be needed at various stages of the
20 syntheses depending upon substituents and functional groups that are present on the reactants.


It is generally preferred that the respective product of each process step be separated from other components of the reaction mixture and subjected to
25 purification before its use as a starting material in a subsequent step. Separation techniques typically include evaporation, extraction, precipitation and filtration. Purification techniques typically include column chromatography (Still, W. C. et. al., *J. Org. Chem.* 1978, 43, 2921), thin-layer chromatography, crystallization and distillation. The structures of the final products,
30 intermediates and starting materials are confirmed by spectroscopic, spectrometric and analytical methods including nuclear magnetic resonance (NMR), mass spectrometry (MS) and liquid chromatography (HPLC). In the descriptions for the preparation of compounds of this invention, ethyl ether, tetrahydrofuran and dioxane are common examples of an ethereal solvent;
35 benzene, toluene, hexanes and cyclohexane are typical hydrocarbon solvents

and dichloromethane and dichloroethane are representative halogenhydrocarbon solvents. In those cases wherein the product is isolated as the acid addition salt the free base may be obtained by techniques known to those skilled in the art. In those cases in which the product is isolated as an acid addition salt, the salt may contain one or more equivalents of the acid.

Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described above and are illustrated more particularly in the schemes that follow. Since the schemes are illustrations, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.

EXAMPLE 1

1-(1-Benzyl-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-yl)-
3-isoquinolin-5-yl-urea
Compound 33




Isoquinolin-5-yl-carbamic acid phenyl ester 1-1 (0.004 mole, 1.06 g) was dissolved in 15 mL of dimethylsulfoxide. Diisopropylethyl amine (0.0044 mole, 0.57 g, 0.8 mL) was added followed by addition of 1-benzyl-6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine hydrochloride 1-2 (0.0044 mole, 1.33 g). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was then poured into 50 mL of water containing 10 mL of 1N sodium hydroxide. The precipitated solid was collected by filtration. This solid

was chromatographed on silica gel eluting with methylene chloride, 3% methanol. Subsequently the product was further purified by recrystallization from ethyl acetate. The title compound **33** (1-(1-benzyl-6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-isoquinolin-5-yl-urea) was obtained as an off-white solid (1.05 g, 0.0024 mole). MS (MH⁺): 438; ¹H NMR (CDCl₃): δ 1.7-1.8 (m, 2H), 2.6-2.9 (m, 4H), 3.6 (s, 3H), 4.1 (m, 1H), 5.8 (d, 1H), 6.4-6.4 (m, 3 H), 6.95 (d, 2H), 7.1 (m, 3H), 7.3 (t, 1H), 7.4-7.5 (m, 2H), 8.2 (d, 2H), 9.0 (s, 1H).

10

EXAMPLE 2

1-(1-Benzyl-6-fluoro-1,2,3,4-tetrahydronaphthalene-2-yl)-3-isoquinolin-5-yl-urea

Compound **38**

15

Isoquinolin-5-yl-carbamic acid phenyl ester **2-1** (0.005 mole, 1.32 g) was dissolved in 15 mL of DMSO (dimethylsulfoxide) followed by the addition of the aminotetralin **2-2**, 1-benzyl-6-fluoro-1,2,3,4-tetrahydro-naphthalen-2-ylamine (0.0044 mole, 1.12 g). The reaction mixture was then stirred at room temperature for 16 hours. The reaction mixture was poured into 50 mL of water containing 10 mL of 1N NaOH (sodium hydroxide). The precipitated solid was collected by filtration. This solid was chromatographed on silica gel eluting with methylene chloride, 3% methanol. Subsequently the product was further purified by recrystallization from ethyl acetate. The title compound **38**, (1-(1-benzyl-6-fluoro-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-isoquinolin-5-yl-urea) was obtained as an off-white solid (1.25 g, 0.00295 mole). MS (MH⁺): 426; ¹H NMR (MeOH): δ 1.35 (m, 1H), 1.9 (m, 1H), 2.1-2.2 (m, 1H), 2.9-3.1 (m,

4H) 3.45 (m, 1H), 4.1-4.2 (m, 1H), 6.7 (t, 1H), 6.8-6.9 (m, 2H), 7.1-7.3 (m, 5H), 7.85 (t, 1H), 8.1 (d, 1H), 8.25 (d, 1H), 8.35 (d, 1H), 8.6 (d, 1H).

5

EXAMPLE 3


1-(1-cyclopropylmethyl-6-fluoro-1,2,3,4-tetrahydronaphthalene-2-yl)-
3-isoquinolin-5-yl-urea
Compound **71**

10 1-Cyclopropylmethyl-6-fluoro-1,2,3,4-tetrahydro-naphthalen-2-ylamine
hydrochloride (127 mg, 0.49 mmol), isoquinolin-5-yl-carbamic acid phenyl ester
(150 mg, 0.49 mmol), and diisopropylethylamine (193 mg, 1.47 mmol) were
combined and stirred at ambient temperature in DMSO (3 mL) overnight. The
product was purified by directly injecting the crude reaction onto a reverse
15 phase prep-HPLC (10-90% water:acetonitrile gradient). The appropriate
fractions were lyophilized to yield 1-(1-cyclopropylmethyl-6-fluoro-1,2,3,4-
tetrahydro-naphthalen-2-yl)-3-isoquinolin-5-yl-urea **71** (68 mg, 0.14 mmol). MS
(MH⁺) 390; ¹H NMR (CD₃OD) δ 0.08-0.87 (m, 2H), 1.60-1.65 (m, 2H), 2.03 (m,
1H), 2.97 (m, 2H), 3.14 (m, 1H), 4.36 (m, 1H), 6.87 (m, 2H), 7.27 (m, 1H), 7.93
20 (t, 1H, J = 2.6 Hz), 8.14 (d, 1H, J = 2.7 Hz), 8.32 (d, 1H, J = 2.2 Hz), 8.47 (d,
1H, J = 2.6 Hz), 8.53 (d, 1H, J = 2.2 Hz), 9.63 (s, 1H). HPLC R_t = 3.63 min (10-
90% water:acetonitrile gradient, 100% pure).

25

EXAMPLE 4

1-(1-Benzyl-6-fluoro-1,2,3,4-tetrahydronaphthalene-2-yl)-
3-isoquinolin-5-ylmethyl-urea
Compound **60**



Isoquinoline **4-1** (0.01 mole, 1.29 g) was dissolved in 50 mL of concentrated H_2SO_4 (sulfuric acid) which had been cooled to 0°C in an ice-water bath. The N-hydroxymethyl trifluoroacetamide was then added in portions. The reaction mixture was stirred at 0°C for 15 minutes and then allowed to warm to room temperature and stirred for 16 hours. The clear light brown reaction mixture was poured onto 200 g of ice then NH_4OH (ammonium hydroxide) was added until the reaction mixture was basic to pH paper. The aqueous mixture was extracted with 100 mL of CH_2Cl_2 (methylene chloride). The organic layer was separated and washed with 2 X 100 mL of brine, dried over Na_2SO_4 (sodium sulfate) and evaporated *in vacuo*. The residue was chromatographed on silica gel eluting with 60/40 hexane/ethyl acetate to yield the trifluoroacetamide **4-2** product as a white crystalline solid (0.008 mole, 2.03g). MS (MH^+): 255; ^1H NMR (CDCl_3): δ 5.0 (s, 2H), 7.6 (t, 1H), 7.8 (d, 1H), 7.95 (d, 1H), 8.1 (d, 1H), 8.5 (d, 1H), 9.2 (s, 1H).

The trifluoroacetamide **4-2** from step A (0.006 mole, 1.53 g) was dissolved in 50 mL of methanol. Sodium borohydride (0.02 mole, 0.8 g) was then added and the reaction mixture was stirred at room temperature for 2 hours. Thin layer chromatography (silica gel, 50/50 hexane/ethyl acetate) showed the reaction to be nearly complete. An additional amount of sodium borohydride was added (0.01 mole, 0.4 g) and stirring was continued for

another 1 hour. The reaction mixture was evaporated *in vacuo*. The residue was taken up in 50 mL of CH₂Cl₂ and then washed with 2 X 50 mL of brine, dried over Na₂SO₄ and evaporated *in vacuo* to yield the amine product **4-3** as a clear oil (0.005 mole, 0.79 g). MS (MH⁺): 159; ¹H NMR (CDCl₃): δ 4.3 (s, 2H), 7.5 (t, 1H), 7.7 (d, 1H), 7.8 (d, 1H), 7.9 (d, 1H), 8.5 (d, 1H), 9.2 (s, 1H).

The amine **4-3** from step B (0.005 mole, 0.79 g) was dissolved in 20 mL of tetrahydrofuran (THF). Pyridine (0.0055 mole, 0.44g, 0.44 mL) was added followed by the careful addition of phenylchloroformate (0.0055 mole, 0.86 g, 0.69 mL). The reaction mixture immediately turned yellow and turbid. Stirring at room temperature was continued for 2 hours. The reaction mixture was evaporated *in vacuo*. The residue was taken up in 50 mL of dichloromethane, washed with 2 X 100 mL saturated sodium bicarbonate then 2 X 100mL of water. The organic layer was dried over sodium sulfate and evaporated *in vacuo* to give a thick slightly yellow oil. This oil was triturated with diethylether and then treated with 1M HCl/diethylether to give the carbamate hydrochloride product **4-4** as an off-white solid. MS (MH⁺): 279; ¹H NMR (MeOH): δ 4.6 (s, 2H), 6.8 (m, 1H), 7.1-7.4 (m, 4H), 7.9 (t, 2H), 8.1 (d, 1H), 8.5 (d, 1H), 8.8 (d, 1H), 9.8 (s, 1H).

20

The carbamate hydrochloride **4-4** from step C (0.0005 mole, 0.139 g) was dissolved in 2 mL of dimethylsulfoxide. Diisopropylethyl amine (0.0011 mole, 0.142 g, 0.19 mL) was added followed by addition of 1-benzyl-6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine hydrochloride (0.00055 mole, 0.297 g). The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was then poured into 20 mL of water containing 5 mL of 1N sodium hydroxide and stirred at room temperature for 15 minutes. The precipitated solid was collected by filtration. This cream colored powder was recrystallized from ethyl acetate/hexane to afford the title product **60**, 1-(1-benzyl-fluoro-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-isoquinolin-5-yl-methyl urea as a white chalky powder (0.000015 mole, 0.065 g). MS (MH⁺): 440; ¹H NMR (CDCl₃): δ 1.8-2.0 (m, 2H), 2.8-3.0 (m, 4H), 4.1 (m 1H), 4.35 (d, 1H), 4.5 (m,

30

1H), 4.8 (d, 2H), 6.6-6.8 (m, 4H), 7.1-7.3 (m, 4H), 7.5 (t, 1H), 7.6 (d, 1H), 7.8 (d 1H), 7.9 (d, 1H), 8.6 (d, 1H), 9.2 (s, 1H).

5

EXAMPLE 5

1-(1-Benzyl-6-fluoro-1,2,3,4-tetrahydronaphthalene-2-yl)-3-(7-hydroxy-naphthalen-1-yl)-urea
Compound 67

10 8-Amino-naphthalen-2-ol (74 mg, 0.46 mmol) was added to a solution of 1-benzyl-2-isocyanato-6-methoxy-1,2,3,4-tetrahydro-naphthalene (136 mg, 0.46 mmol) in acetonitrile (2 mL). The reaction was microwaved for 5 min at 100 °C. The solvent was stripped off and the residue chromatographed on a silica column using chloroform as eluant to yield title compound 68 (95 mg, 15 45%) MS (MH⁺) 453; ¹H NMR (CD₃OD) δ 1.87 (m, 1H), 2.02 (m, 1H), 2.89-2.93 (m, 4H), 3.38 (m, 1H), 3.73 (s, 3H), 4.05 (m, 1H), 6.52 (d, 1H, J = 3 Hz), 6.65 (m, 2H), 7.09 (d, 3H, J = 2.4 Hz), 7.14 (d, 1H, J = 2.2 Hz), 7.21 (d, 2H, J = 2.3 Hz), 7.26 (d, 2H, J = 3.0 Hz), 7.52-7.58 (m, 2H), 7.72 (d, 1H, J = 2.9 Hz). HPLC R_t = 4.73 min (10-90% water:acetonitrile gradient, 100% pure).

20

EXAMPLE 6

1-(1-Benzyl-6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-(4-hydroxy-3-methoxy-benzyl)-thiourea
Compound 3

25

Sodium hydride (60 % in oil, 2.81 g, 10 mmol) was added to a solution of 4-hydroxy-3-methoxy-benzonitrile (10 g, 67 mmol) in DMF (100 mL) at 0° C. Mixture was allowed to stir at ambient temperature for 30 min. Bromomethylmethyl ether (6.4 mL, 70 mmol) was added to the resultant 30 solution, and the solution was stirred at rt for 2 h. The solution was poured into ice water (~400 mL). The product, 3-Methoxy-4-methoxymethoxy-benzonitrile, was collected by filtration, washed generously with water, and allowed to air dry to give the product as a colorless solid 11.75 g (91%). The purity of the

product was estimated to be (95 % by HPLC and H NMR, and the product was used without further purification in the subsequent step). ^1H NMR (CDCl_3): δ 3.51 (s, 3 H), 3.91 (s, 3 H), 5.23 (s, 2 H), 7.12 (d, $J = 1.8$ Hz, 1 H), 7.20 (d, $J = 8.4$ Hz, 1 H) and 7.25 (d of d, $J = 8.4$ & 1.8 Hz, 1 H).

5

A solution of 3-methoxy-4-methoxymethoxy-benzonitrile (9.1 g, 47.1 mmol) in THF (75 mL) was slowly added, via an addition funnel, to a solution of LAH in THF (1.0 M, 100 mL, 100 mmol) cooled on an ice bath. The resultant solution was heated to reflux for 4 h. The solution was cooled on an ice bath.

10 Sequential addition of water (3.5 mL), 15% aqueous sodium hydroxide (7 mL) and water (10 mL) was carefully done via an addition funnel. The inorganics were removed by filtration, and washed generously with THF. The combined organic solutions were dried over sodium sulfate, and the solvent was evaporated under vacuum to give the product, 5.3 g (57%). The product was

15 used without purification in the subsequent step. ^1H NMR (CDCl_3): δ 1.58 (br s, 1 H), 3.51 (s, 3 H), 3.82 (s, 2 H), 3.89 (s, 3 H), 5.21 (s, 2 H), 6.82 (d of d, $J = 8.4$ & 1.8 Hz, 1 H), 6.90 (d, $J = 1.8$ Hz) and 7.10 (d, $J = 8.1$ Hz, 1 H). MS: m/z 198 ($\text{M}+\text{H}$) $^+$.

20 A solution of 3-methoxy-4-methoxymethoxybenzylamine (5.3 g, 26.9 mmol) in ethyl acetate (50 mL) was added, via an addition funnel) to a solution of thiophosgene (2.15 mL, 28.2 mmol) and triethylamine (7.87 mL, 56.5 mmol) in ethyl acetate (30 mL) at 0° C. The resultant solution was stirred at ambient temperature overnight. The solution was washed with saturated aqueous

25 sodium bicarbonate and dried over sodium sulfate. The solvent was evaporated in vacuo, and the residue was purified by flash chromatography on silica gel eluted with ethyl acetate/hexanes (1/9 to 3/7) to give the product, 4-isothiocyanatomethyl-2-methoxy-1-methoxymethoxy-benzene, as a waxy tan solid, 4.9 g (76%). ^1H NMR (CDCl_3): δ 3.51 (s, 3 H), 3.91 (s, 3 H), 4.64 (s, 2

30 H), 5.23 (s, 2 H), 6.83 (m, 2 H) and 7.14 (d, $J = 8$ Hz).


A solution of *cis*-1-benzyl-6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine hydrochloride (0.306 g, 1.01 mmol), diisopropylethylamine (0.264 mL,

1.51 mmol) and 4-isothiocyanatomethyl-2-methoxy-1-methoxymethoxy-benzene (0.253 g, 1.06 mmol) in acetonitrile (10 mL) was stirred at ambient temperature overnight. The solvent was evaporated in vacuo, and the residue was purified by reverse phase preparative HPLC, on a C18 column eluted with a gradient of 40 to 90 % acetonitrile in water with 0.1 % TFA, to give the product, 1-(1-benzyl-6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-(3-methoxy-4-methoxymethoxy-benzyl)-thiourea, 0.21 g (41 %). ¹H NMR (CDCl₃): δ 1.64 (br s, 1 H), 1.85 (m, 1 H), 2.04 (m, 1 H), 2.63 (m, 1 H), 2.82 (m, 2 H), 2.98 (m, 1 H), 3.33 (m, 1 H), 3.49 (s, 3 H), 3.78 (s, 3 H), 3.84 (s, 3 H), 4.32 (br s, 2 H), 5.19 (s, 2 H), 5.7 (br s, 1 H), 6.0 (br s, 1 H), 6.64 (m, 3 H), 6.80 (s, 1 H), 6.91 (d, J = 8.4 Hz, 1 H), 7.03 (d, J = 8.2 Hz, 1 H) and 7.11 to 7.28 (m, 5 H). MS: *m/z* 507 (M+H)⁺.

A solution of 1-(1-benzyl-6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-(3-methoxy-4-methoxymethoxy-benzyl)-thiourea (0.21 g, 0.42 mmol) in isopropanol/acetonitrile (10 mL/10 mL) was treated with concentrated hydrochloric acid (1 mL) and stirred at ambient temperature for 30 min. The solvent was evaporated under a stream of nitrogen, and the residue was partitioned between dichloromethane and water. The organic layer was collected and the solvent was evaporated. The product was purified by flash chromatography, on silica gel eluted with ethyl acetate/hexanes (1/2) to give the title product, compound 3, as a colorless solid, 0.184 g (95 %). ¹H NMR (CDCl₃): δ 1.83 (m, 1 H), 2.05 (m, 1 H), 2.67 (m, 1 H), 2.81 (m, 2 H), 3.03 (br s, 1 H), 3.78 (s, 3 H), 3.84 (s, 3 H), 4.25 (br s, 2 H), 5.61 (s, 2 H), 6.59 to 6.68 (m, 3 H), 6.74 (s, 1 H), 6.80 (d, J = 8 Hz, 1 H), 6.94 (d, J = 8.5 Hz, 1 H) and 7.12 to 7.29 (m, 5 H). MS: *m/z* 463 (M+H)⁺.

EXAMPLE 7

1-(1-Benzyl-6-fluoro-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-(2-oxy-isoquinolin-5-yl)-urea
Compound 85



The aminotetralin urea **1** (0.150 g, 0.00035 mol) was dissolved in 5 mL of dichloromethane. The solid *m*-chloroperbenzoic acid (0.066g, 0.00039 mol) was added and the reaction mixture was stirred at room temperature for 16 hours. Thin layer chromatography (silica gel, CH₂Cl₂/5% MeOH) indicated the presence of starting material. An additional portion of MCPBA was added (0.050 g) and stirring at room temperature was continued for another 4 hours. At the end of this period, the reaction was complete was indicated by TLC.

Saturated sodium bicarbonate (25 mL) was cautiously added to the reaction mixture and the organic layer was separated. The organic layer was washed with 25 mL of brine, dried over Na₂SO₄ and evaporated *in vacuo*. The residue was purified by flash chromatography on silica gel eluting with CH₂Cl₂/4% MeOH. The product **2** was obtained as a light brown powder (0.120 g, 0.00027 mol). ¹H NMR (CD₃OD): δ 1.8-2.1 (m, 2H), 2.9-3.1 (m, 4H), 3.6 (m, 1H), 4.2 (m, 1H), 6.6-6.9 (m, 3 H), 7.1-7.3 (m, 5H), 7.6-7.8 (m, 2H), 8.0 (bd, 1H), 8.2 (bt, 2H), 8.9 (s, 1H); MS (M⁺): 442.

EXAMPLE 8

1-(1-Benzyl-6-fluoro-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-(1-chloro-isoquinolin-5-yl)-urea
Compound **79**


(1-Chloro-isoquinolin-5-yl)-carbamic acid phenyl ester (150 mgs, 0.5 mmol), 1-Benzyl-6-fluoro-1,2,3,4-tetrahydro-naphthalen-2-ylamine hydrochloride (146 mgs, 0.5 mmol), and sodium bicarbonate (42 mgs, 0.5 mmol) were combined and stirred for one hour in DMSO (4ml) at ambient temperature. The product was purified by directly injecting the crude reaction

onto a reverse phase prep-HPLC (10-90% water:acetonitrile gradient). The appropriate fractions were lyophilized to yield 1-(1-Benzyl-6-fluoro-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-(1-chloro-isoquinolin-5-yl)-urea (64 mgs, 28%) MS (MH⁺) 459; ¹H NMR (CD₃OD) δ 1.93-2.06 (m, 1H), 2.09-2.13 (m, 1H), 2.91-3.07 (m, 4H), 3.40-3.42 (m, 1H), 4.07-4.10 (s, 1H), 6.69-6.78 (m, 1H), 6.80-6.89 (m, 2H), 7.12-7.26 (m, 5H), 7.72 (t, 1H, J = 8.2 Hz), 7.83 (d, 1H, J = 6.1 Hz), 8.19 (d, 1H, J = 8.6 Hz), 8.17-8.24 (m, 2H). HPLC R_t = 4.04 min (50-90% water:acetonitrile gradient, 100% pure).

10

EXAMPLE 9

1-(1-Benzyl-6-fluoro-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-(1-methyl-isoquinolin-5-yl)-urea
Compound 80




15

A. 1-Methyl-5-aminoisoquinoline (*J. Med Chem.*, **1968**, 11,700), (0.01 mole, 1.58 g) was dissolved in 20 mL of tetrahydrofuran (THF). Pyridine (0.011 mole, 0.88g, 0.88 mL) was added followed by the careful addition of phenylchloroformate (0.011 mole, 1.72 g, 1.4 mL). The reaction mixture immediately turned yellow and turbid. Stirring at room temperature was continued for 4 hours. The reaction mixture was evaporated *in vacuo*. The residue was taken up in 50 mL of dichloromethane, washed with 2 X 100 mL saturated sodium bicarbonate then 2 X 100mL of water. The organic layer was dried over sodium sulfate and evaporated *in vacuo* to give a thick dark yellow-brown oil. This oil was triturated with diethylether to give the carbamate product 1 as a yellowish-brown solid.

25

¹H NMR (CDCl₃): δ 3.0 (bs, 3H), 7.2 (m, 3H), 7.3-7.4 (m, 2H), 7.5-7.6 (m, 2H), 7.8 (bs, 1H), 8.2 (bs, 1H), 8.4 (bt, 1H).

MS (MH⁺): 279




5 B. 1-Methyl-isoquinolin-5-yl-carbamic acid phenyl ester **1** obtained in
 step A (0.001 mole, 0.278 g) was dissolved in 5 mL of dimethylsulfoxide.
 Diisopropylethyl amine (0.0011 mole, 0.14 g, 0.2 mL) was added followed by
 the addition of 1-benzyl-6-fluoro-1,2,3,4-tetrahydronaphthalen-2-ylamine
 hydrochloride **2** (0.0011 mole, 0.321 g). The reaction mixture was stirred at
 10 room temperature for 16 hours. The reaction mixture was then poured into 20
 mL of water containing 5 mL of 1N sodium hydroxide. The precipitated solid
 was collected by filtration. This solid was chromatographed on silica gel eluting
 with a gradient of methylene chloride/ 3-10 % methanol. Subsequently the
 product was further purified by recrystallization from ethyl acetate. The title
 15 compound **3** was obtained as an off-white solid (0.272 g, 0.0006 mole).

^1H NMR (CDCl_3): δ 1.8-1.9 (m, 2H), 2.7-2.8 (m, 4H), 2.95 (s, 3H), 3.2-3.2
 (m, 1H), 4.1-4.2 (m, 1H), 5.1 (d, 1H), 6.4-6.6 (m, 2H), 6.8 (d, 1H), 6.9 (s, 1H),
 7.0 (d, 1H), 7.1-7.2 (m, 2H), 7.4-7.5 (m, 2H), 7.7 (d, 1H), 7.9 (d, 1H), 8.3 (d,
 1H).

20 MS (MH^+): 440

EXAMPLE 10

Spiro[indan-2,1'-(1',2',3',4'-tetrahydronaphthalene)-2'-yl]-3-
 isoquinolin-5-yl-urea
 Compound 122



25

A. 6-Fluoro-3,4-dihydro-1H-naphthalen-2-one (2.472 g, 15.06 mmol) was dissolved in 75 mL THF and cooled on an ice bath with stirring under nitrogen. o-Xylene dibromide (4.378 g, 16.59 mmol) was added to the cooled tetralone solution. Separately potassium tert-butoxide (3.73 g, 33.2 mmol) was slurried in a combination of 75 mL THF and 10 mL tBuOH. The KOtBu slurry was added to the reaction mixture over a period of 15 minutes. The reaction was stirred on the ice bath for one hour then at room temperature for an additional hour after which time the entire reaction mixture was filtered over a pad of celite. The filtrate was evaporated *in vacuo* to give a residue which was taken up in 100 mL diethyl ether, washed twice with 50 mL 1N HCl and once with 50 mL brine. The organics were dried with MgSO₄, filtered and evaporated *in vacuo* to give the crude product which was purified by chromatography over silica gel eluting with 0- 10 % EtOAc in hexanes. Evaporation of the proper fractions yielded the product as an off-white solid (3.09 g, 11.6 mmol). ¹H NMR (CDCl₃): δ 7.33-7.17 (m, 4H), 7.07 (q, 1H), 6.93 (dd, 1H), 6.82 (dt, 1H), 3.81 (d, 2H), 3.19 (m, 4H), 2.79 (t, 2H).

B. The spirotetralone from step A (3.06 g, 11.5 mmol) was dissolved in 150 mL MeOH along with NH₄OAc (13.57 g, 176.1 mmol) and NaCNBH₃ (3.7 g, 59 mmol). The mixture was kept under a nitrogen atmosphere and heated to reflux for 3 hours. The reaction was concentrated *in vacuo*, mixed with 100 mL water and basified with 25 mL 50% NaOH. The basified mixture was extracted three times with 50 mL methylene chloride. The combined organics were washed once with 50 mL brine, dried with Na₂SO₄, filtered and concentrated *in vacuo* to give the crude free base. The free base was then dissolved in diethyl ether, acidified with ethereal HCl and evaporated *in vacuo*. The solid residue was triturated with 50 mL hot EtOAc, filtered and dried to yield the product HCl salt as a white powder (2.867 g, 9.44 mmol). MS: M+H⁺ = 268.1; ¹H NMR (d₆-DMSO): δ 8.22 (br s, 3H), 7.33 (d, 1H), 7.24 (m, 3H), 7.01 (d, 1H), 6.87 (d, 2H), 3.71 (m, 1H), 3.52 (d, 1H), 3.38 (d, 1H), 3.11 (d, 1H), 2.97 (m, 3H), 2.15 (m, 2H).


C. The spirotetralin salt from step B (0.304 g, 1.00 mmol) was

dissolved in 6 mL DMSO along with $i\text{Pr}_2\text{NEt}$ (0.38 mL, 2.2 mmol) and 5-aminoisoquinoline phenylcarbamate (0.308 g, 1.02 mmol). The reaction was stirred overnight then poured into 100 mL water. The solid which formed was collected by filtration, rinsed with water then triturated first with diethyl ether and finally with hexanes to give the product urea as a tan powder (0.287 g, 0.66 mmol). MS: $M+H^+ = 438.4$; ^1H NMR (d_6 -DMSO): δ 9.27 (s, 1H), 8.67 (s, 1H), 8.52 (d, 1H), 8.38 (d, 1H), 7.89 (d, 1H), 7.72 (d, 1H), 7.61 (t, 1H), 7.32 (d, 1H), 7.70 (m, 3H), 7.04 (dd, 1H), 7.00-6.76 (m, 3H), 4.26 (m, 1H), 3.39 (m, 2H), 3.19 (d, 1H), 3.05-2.88 (m, 3H), 2.18-1.92 (m, 2H).

10

EXAMPLE 11

Experimental Protocol for Resolution



15

A. 6-F- α -(3-trifluoromethylbenzyl)- β -aminotetralin (1.931 g, 5.97 mmol) was dissolved in 50 mL 1:1 iPrOH/MeOH. (R)-(-)-O-Methyl mandelic acid (0.992 g, 5.97 mmol) was added and the mixture was heated to reflux. An additional 170 mL 1:1 iPrOH/MeOH was added to bring the total volume of solvent to 220 mL and make a clear solution. The solution was then allowed to sit and cool overnight. The resulting crystalline material was collected by filtration, rinsed with a small amount of 1:1 iPrOH/MeOH and dried. This batch of crystals was re-crystallized as before from 125 mL 1:1 iPrOH/MeOH. After filtration and drying, 625 mg of the salt of the aminotetralin with (R)-(-)-O-methyl mandelic acid (1.28 mmol) were obtained.

B. The combined mother liquors, filtrates, and rinsates from above were evaporated under vacuum. The residue was partitioned between 200 mL Et₂O and 100 mL 10% Na₂CO₃ solution. The organics were separated,

washed again with 100 mL 10% Na₂CO₃ and then with 100 mL brine. The organics were dried over Na₂SO₄, treated with charcoal, filtered and evaporated *in vacuo* to give the recovered aminotetralin (1.399 g, 4.33 mmol). To this was added (S)-(+)-O-methyl mandelic acid (0.719 g, 4.33 mmol) and
5 190 mL 1:1 iPrOH/MeOH and the mixture was heated to reflux to give a clear solution. The solution was then allowed to sit and cool overnight. The resulting crystalline material was collected by filtration, rinsed with a small amount of 1:1 iPrOH/MeOH and dried. This batch of crystals was re-crystallized as before from 140 mL 1:1 iPrOH/MeOH. After filtration and drying,
10 759 mg of the salt of the aminotetralin with (S)-(+)-O-methyl mandelic acid (1.55 mmol) were obtained.







C. Each of the mandelate salts thus prepared was separately suspended in 100 mL Et₂O, washed with 50 mL 10% Na₂CO₃ then with 50 mL brine. The organics were then dried with Na₂SO₄, filtered and evaporated *in*
15 *vacuo*. The residue was dissolved in MeOH and excess ethereal HCl was added. The mixture was evaporated *in vacuo* and the resulting solids were triturated with hexanes, filtered and dried under vacuum.

The HCl salt derived from the aminotetralin resolved with (R)-(-)-O-methyl mandelic acid (0.422 g, 1.17 mmol): $[\alpha]_D = -159.0^\circ$ (c = 1, MeOH).

20 The HCl salt derived from the aminotetralin resolved with (S)-(+)-O-methyl mandelic acid (0.506 g, 1.41 mmol): $[\alpha]_D = +159.1^\circ$ (c = 1, MeOH).

The ¹H NMR spectra of the hydrochloride salts were identical: ¹H NMR (d6-DMSO): 8.64 (br s, 3H), 7.59 (d, 1H), 7.52 (t, 1H), 7.42 (m, 2H), 6.99 (dd, 1H), 6.63 (dt, 1H), 5.91 (dd, 1H), 3.59 (m, 1H), 3.34-3.19 (m, 2H), 3.08 (m, 1H),
25 2.92 (m, 1H), 2.59 (d, 1H), 2.08 (m, 2H). MS: M+H⁺ = 324.1

D. Other resolutions were performed in a similar manner to yield the results as shown in the table below.

Racemic Amine	Resolving Acid	Solvent	$[\alpha]_D$ of the HCl Salts (c=1, MeOH)
		1:1 iPrOH:MeOH	+159.1° / -159.0°
		iPrOH	+213.0° / -216.6°
		14-67:1 EtOH:H ₂ O	+70.7° / -71.4°

Using the procedures of the Examples above and the appropriate reagents, starting materials and purification methods known to those skilled in the art, other compounds of the present invention may be prepared including, but not

5 limited to:

Table 1. Mass Spectral Data for Selected Compounds			
No.	Substituents on Formula (Ia)	MW (calc)	Parent Peak (obs)
3	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3-OMe-4-OH)Ph, and X is S; (<i>cis</i>)	462.6	463.1
4	R ₁ is H, R ₂ is 3-Pyridinyl, m is 1, L is -CH ₂ -, R ₃ is (3-OMe-4-(Methoxymethyleneoxy)Ph, and X is S; (<i>cis</i>)	477.6	477.8
5	R ₁ is H, R ₂ is 3-Pyridinyl, m is 1, L is -CH ₂ -, R ₃ is (3-OMe-4-OH)Ph, and X is S; (<i>cis</i>)		
6	R ₁ is 6-OMe, R ₂ is 3-Pyridinyl, m is 1, L is -CH ₂ -, R ₃ is (3-OMe-4-OH)Ph, and X is S; (<i>cis</i>)	463.6	464.1
7	R ₁ is 6-OMe, R ₂ is -CH=CH ₂ , m is 1, L is -CH ₂ -, R ₃ is (3-OMe-4-(Methoxymethyleneoxy)Ph, and X is S; (<i>cis</i>)	456.6	457.1

8	R ₁ is 6-OMe, R ₂ is 4-Imidazolyl, m is 1, L is -CH ₂ -, R ₃ is (3-OMe-4-OH)Ph, and X is S;	452.6	453.1
9	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3,4-methylenedioxy)Ph, and X is O;	444.5	445.1
10	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3,4-diOMe)Ph, and X is O;	460.6	461.1
11	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (4- <i>t</i> Bu)Ph, and X is O;	456.6	457.2
12	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ CH ₂ -, R ₃ is (4-Cl)Ph, and X is O;	449.0	449.1
13	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ CH ₂ -, R ₃ is (3,4-diOMe)Ph, and X is O;	474.6	475.1
14	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3,4-methylenedioxy)Ph, and X is S;	460.6	461.1
15	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3,4-diOMe)Ph, and X is S;	476.6	477.1
16	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (4- <i>t</i> Bu)Ph, and X is S;	472.7	473.1
17	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ CH ₂ -, R ₃ is (4-Cl)Ph, and X is S;	465.1	465.0
18	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ CH ₂ -, R ₃ is (3,4-diOMe)Ph, and X is S;	490.7	491.1
19	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3-OMe-4-OH)Ph, and X is O;	446.5	447.1
21	R ₁ is H, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3-OMe-4-(Methoxymethyleneoxy)Ph, and X is S; (<i>cis</i>)	476.6	476.7
23	R ₁ is H, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3-OMe-4-OH)Ph, and X is S; (<i>cis</i>)	432.6	433.1
24	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (4-N(Me)(C ₅ H ₁₁))Ph, and X is O;	499.7	500.3
25	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (4-[N(Me)(cyclohexyl)])Ph, and X is O;	511.7	512.3

26	R ₁ is 6-F, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3,4-diOMe)Ph, and X is S; (<i>cis</i>)	450.6	451.1
27	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (4-CF ₃)Ph, and X is O;	468.5	469.3
28	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3,4-diCl)Ph, and X is O;	469.4	469.1
29	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ CH ₂ -, R ₃ is (3,4-diCl)Ph, and X is O;	483.4	483.7
30	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (4-CF ₃)Ph, and X is S;	484.6	485.6
31	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is (3,4-diCl)Ph, and X is S;	485.5	485.0
32	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ CH ₂ -, R ₃ is (3,4-diCl)Ph, and X is S;	499.5	499.0
33	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	437.5	438.4
34	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 3-quinolinyl, and X is O;	437.5	438.7
35	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 8-(2-naphtholyl), and X is O;	452.5	453.1
36	R ₁ is H, R ₂ is H, m is 0, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	317.4	359.1 (MeCN)
37	R ₁ is 6-F, R ₂ is H, m is 0, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	335.4	336.2
38a	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (racemate)	425.5	426.3
38b	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (enantiomer 1)	425.5	426
38c	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (enantiomer 2)	425.5	426
39	R ₁ is 6-Br, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	486.4	485.9

40	R ₁ is 6,7-diOMe, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	467.6	468.2
41	R ₁ is 7-Cl, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	441.9	442.0
42	R ₁ is 5-Cl, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	441.9	441.9
43	R ₁ is H, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	407.5	408.2
44	R ₁ is 6-OMe, R ₂ is (3-Cl)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	472.0	472.3
45	R ₁ is 6-OMe, R ₂ is 3-Pyridinyl, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	438.5	439.0
46	R ₁ is 6-OMe, R ₂ is (3-Cl)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>trans</i>)	472.0	471.9
47	R ₁ is 6-OMe, R ₂ is 3-Pyridinyl, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>trans</i>)	438.5	438.8
48	R ₁ is 6,7-diOMe, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>trans</i>)	467.6	468.2
49	R ₁ is 6-OMe, R ₂ is (2-Cl)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	472.0	473.3
50	R ₁ is 6-OMe, R ₂ is (4-Cl)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	472.0	472.3
51	R ₁ is 6-OMe, R ₂ is H, m is 0, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	347.4	348.6
52	R ₁ is 6-OMe, R ₂ is (2-Cl)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>trans</i>)	472.0	472.2
53	R ₁ is 6-OMe, R ₂ is (2-CF ₃)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	505.5	506.4
54	R ₁ is 6-OMe, R ₂ is (3-CF ₃)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	505.5	506.4
55	R ₁ is 6-OMe, R ₂ is (4-CF ₃)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	505.5	506.3

56	R ₁ is 6-OH, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	423.5	424.2
57	R ₁ is H, R ₂ is -CH=CH ₂ , m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	357.4	358.2
58	R ₁ is 6-Br, R ₂ is H, m is 0, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	396.3	397.9
59	R ₁ is 6-Cl, R ₂ is H, m is 0, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	351.8	351.9
60	R ₁ is 6-F, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is 5-isoquinolinyl, and X is O;	439.5	440.2
61	R ₁ is 7-Cl, R ₂ is H, m is 0, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	351.8	351.9
62	R ₁ is 8-Cl, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	441.9	441.9
63	R ₁ is 6-OMe, R ₂ is (4-CN)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	462.6	463.2
64	R ₁ is 6-OMe, R ₂ is (4-Br)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	516.4	517.9
65	R ₁ is 6-Cl, R ₂ is CN, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	390.0	390.9
66	R ₁ is 6,7-diF, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	443.5	443.9
67	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 8-(2-naphtholyl), and X is O;	440.5	441.1
68	R ₁ is 6-OMe, R ₂ is -CH=CH ₂ , m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	387.5	388.4
69	R ₁ is 6-F, R ₂ is -CH=CH ₂ , m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	375.4	376.4
70	R ₁ is 6-OMe, R ₂ is (4-OMe)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>trans</i>)	467.6	468.2
71	R ₁ is 6-F, R ₂ is Cyclopropyl, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	389.5	390.5

72	R ₁ is 6-OMe, R ₂ is (4-OMe)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	467.6	468.2
73	R ₁ is 6-OMe, R ₂ is (2-OMe)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	467.6	468.2
74	R ₁ is 6-OMe, R ₂ is (4-Benzoyloxy)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	543.4	544.1
75	R ₁ is 6-OMe, R ₂ is Ph, m is 1, L is -CH ₂ -, R ₃ is 4-Pyridinyl, and X is O;		
76	R ₁ is 6-F, R ₂ is 2-Thienyl, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	431.5	432.0
77	R ₁ is 6-OMe, R ₂ is (2,6-diF)Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	473.5	474.4
81a	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 3-Me-5-isoquinolinyl, and X is O; (<i>cis</i>) (enantiomer 1)	439.5	440
81b	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 3-Me-5-isoquinolinyl, and X is O; (<i>cis</i>) (enantiomer 2)	439.5	440
85a	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl-N-oxide, and X is O; (<i>cis</i>) (enantiomer 1)	441.5	442
85b	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl-N-oxide, and X is O; (<i>cis</i>) (enantiomer 2)	441.5	442
86	R ₁ is 6-Cl, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O;	442	442
87	R ₁ is 6-OCH ₃ , R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>) (enantiomer 2)	437.5	438.2
88	R ₁ is 6-F, R ₂ is 3-furanyl, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	415.5	416.4
89	R ₁ is 6-OCH ₃ , R ₂ is 3-thienyl, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O	443.6	444.4
90	R ₁ is 6-OCH ₃ , R ₂ is 2,4 di-F Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinolinyl, and X is O; (<i>cis</i>)	473.5	474.4

91	R ₁ is 6-OCH ₃ , R ₂ is 2,4 di-F Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O; (<i>trans</i>)	473.5	474.5
92	R ₁ is 6-OCH ₃ , R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 1</i>)	437.5	438.1
93	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 1</i>)	425.5	426.4
94	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 2</i>)	425.5	426.6
95	R ₁ is 6-Cl, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O; (<i>cis</i>)	442.0	442.5
96	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny-N-oxide, and X is O; (<i>cis</i>) (<i>enantiomer 1</i>)	441.5	442.7
97	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny-N-oxide, and X is O; (<i>cis</i>) (<i>enantiomer 2</i>)	441.5	442.8
98	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 4-Cl-5-isoquinoliny, and X is O; (<i>cis</i>)	460.0	460
99	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 4-Cl-5-isoquinoliny, and X is O; (<i>cis</i>)	460.0	460
100	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 3-methyl-5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 1</i>)	439.5	440.3
101	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 3-methyl-5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 2</i>)	439.5	440.3
102	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-methyl-5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 1</i>)	439.5	440.5
103	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-methyl-5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 2</i>)	439.5	440.5

104	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-Cl-5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 1</i>)	459.9 6	459.6
105	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-Cl-5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 2</i>)	460.0	459.9
106	R ₁ is 6-Cl, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny-N-oxide, and X is O; (<i>cis</i>)	457.9	459.0
107	R ₁ is 6-F, R ₂ is 4-CF ₃ Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O; (<i>cis</i>)	493.5	494.5
108	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1,3-diCl- 5-isoquinoliny, and X is O; (<i>cis</i>)	494.4	494
109	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1,3-diCl-5-isoquinoliny, and X is O; (<i>cis</i>)	494.4	494
110	R ₁ is 6-F, R ₂ is 3-CF ₃ Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O; (\pm <i>cis</i>)	493.5	494.6
111	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 8-Cl-5-isoquinoliny, and X is O; (<i>cis</i>)	460.0	460
112	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-piperidiny-5-isoquinoliny, and X is O; (<i>cis</i>)	508.6	509
113	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-OCH ₃ -5-isoquinoliny, and X is O; (<i>cis</i>)	455.5	456
114	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-F- 5-isoquinoliny, and X is O; (<i>cis</i>)	443.5	444
115	R ₁ is 6-F, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-N,N-dimethyl- 5-isoquinoliny, and X is O; (<i>cis</i>)	468.6	469
116	R ₁ is 6-Cl, R ₂ is nil, m is nil, R ₃ is 1-CH ₃ -5-isoquinoliny, and X is O	365.9	366.0
117	R ₁ is 6-Cl, R ₂ is nil, m is nil, R ₃ is 1-Cl-5-isoquinoliny, and X is O	386.3	386.1
118	R ₁ is 6-F, R ₂ is 3-CF ₃ Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O; (<i>cis</i>)(<i>enantiomer 1</i>)	493.5	494.6
119	R ₁ is 6-F, R ₂ is 3-CF ₃ Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O; (<i>cis</i>)(<i>enantiomer 2</i>)	493.5	494.6

120	R ₁ is 6-F, R ₂ is 3-CF ₃ Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny-N-oxide, and X is O; (<i>cis</i>) (<i>enantiomer 1</i>)	509.5	510.2
121	R ₁ is 6-F, R ₂ is 3-CF ₃ Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny-N-oxide, and X is O; (<i>cis</i>) (<i>enantiomer 2</i>)	509.5	510.2
122	R ₁ is 6-F, R ₂ is spiro-2-indanyl, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O	437.5	438.4
123	R ₁ is 6-F, R ₂ is 4-Cl,3-CF ₃ Ph, m is 1, L is a direct bond, R ₃ is 5-isoquinoliny, and X is O; (<i>cis</i>)	527.9	528.3
124	R ₁ is 6-Cl, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-CH ₃ -5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 1</i>)	442.0	442.2
125	R ₁ is 6-Cl, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-CH ₃ -5-isoquinoliny, and X is O; (<i>cis</i>) (<i>enantiomer 2</i>)	442.0	442.2
126	R ₁ is 6-Cl, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-CH ₃ -5-isoquinoliny, and X is O; (<i>trans</i>) (<i>enantiomer 1</i>)	442.0	442.2
127	R ₁ is 6-Cl, R ₂ is Ph, m is 1, L is a direct bond, R ₃ is 1-CH ₃ -5-isoquinoliny, and X is O; (<i>trans</i>) (<i>enantiomer 2</i>)	442.0	442.2

Biological Examples

EXAMPLE 1

5

Human or Rat VR₁ Binding Assay

Compounds of the present invention were tested for their ability to inhibit the binding of [³H] RTX to hVR₁ receptors in a [³H] RTX binding assay as previously described (Zhang, Sui-Po. Improved ligand binding assays for vanilloid receptors. PCT Int. Appl. (2002), 29 pp. CODEN: PIXXD2 WO 10 0233411 A1 20020425 AN 2002:315209; Grant, Elfrida R.; Dubin, Adrienne

- E.; Zhang, Sui-Po; Zivin, Robert A.; Zhong, Zhong Simultaneous intracellular calcium and sodium flux imaging in human vanilloid receptor 1 (VR1)-transfected human embryonic kidney cells: a method to resolve ionic dependence of VR1-mediated cell death. *Journal of Pharmacology and Experimental Therapeutics* (2002), 300(1), 9-17.)

HEK293 cells were transfected with human VR1 vanilloid receptors and washed with Hank's Balanced Salt Solution, dissociated with cell dissociation buffer (Sigma), and then centrifuged at 1000 x g for 5 min. Cell pellets were homogenized in cold 20 mM HEPES buffer, pH 7.4, containing 5.8 mM NaCl, 320 mM sucrose, 2 mM MgCl₂, 0.75 CaCl₂ and 5 mM KCl and centrifuged at 1000 x g for 15 min. The resultant supernate was then centrifuged at 40000 x g for 15 min. The pelleted membranes were kept in an -80°C freezer.

Approximately 120 µg protein/ml from membranes were incubated with indicated concentrations of [³H] RTX in 0.5 ml of the HEPES buffer (pH 7.4) containing 0.25 mg/mL fatty acid-free bovine serum albumin at 37°C for 60 min. The reaction mixture was then cooled to 4°C, 0.1 mg α₁-acid glycoprotein added to each sample and incubated at 4°C for 15 min. The samples were centrifuged at 18500 x g for 15 min. The tip of the microcentrifuge tube containing the pellet was cut off. Bound radioactivity was quantified by scintillation counting. Non-specific binding was tested in the presence of 200 nM unlabeled RTX.

Alternatively, a binding assay using rat tissue was used. Rat spinal cord was homogenized twice with a Polytron and centrifuged at 3000 rpm for 10 min in HEPES buffer containing 20 mM HEPES, pH 7.4, NaCl 5.8 mM, sucrose 320 mM, MgCl₂ 2 mM, CaCl₂ 0.75 mM and KCl 5 mM. The supernatant was then centrifuged at 18,000 rpm for 20 min. The pellet was saved in a tube and 10 ml assay buffer was added into the tube. The pellet and buffer were mixed with a Polytron. The assay contained 120 µg/ml membrane protein and 0.3-0.6 nM [³H]-RTX (NEN, Boston) in a total volume of 0.5 ml HEPES buffer. Following-incubation for 60 min at 37C, the samples

were cooled down on ice, and 100 mg of α -acid glycoprotein were added into the samples. After centrifugation at 13,000 rpm for 15 min, the supernatant was aspirated and the tips of tubes were cut off and placed into 6 ml vials.

Data were calculated according to the equation: % inhibition = (total binding-
5 binding)*100/(total binding - non specific binding). K_i value values were calculated using a Prism program.

EXAMPLE 2

Human VR₁ Functional Assay

10

The functional activity of the test compounds was determined by measuring changes in intracellular calcium concentration using a Ca^{++} -sensitive fluorescent dye and FLIPRTM technology. Increases in Ca^{++} concentration were readily detected upon challenge with capsaicin.

15

HEK293 Cells expressing human VR1 were grown on poly-D-lysine coated 96 well black-walled plates (BD 354640) and 2 days later loaded with Fluo-3/AM for 1 hour and subsequently tested for agonist-induced increases in intracellular Ca^{2+} levels using FLIPRTM technology. Cells were challenged with
20 test compounds (at varying concentrations) and intracellular Ca^{++} was measured for 3 min prior to the addition of capsaicin to all wells to achieve a final concentration of 0.015 μ M eliciting ~80% maximal response. EC_{50} or IC_{50} values were determined from dose-response studies.

25

Table 2. Vanilloid In vitro assay data

Compound No.	hVR1 K_i (nM)	Rat VR1 K_i (nM)	IC_{50} or EC_{50} (nM)
1	2530	NT	780
2	31600	NT	NT
3	98.9	NT	12
4	NT	NT	460

5	NT	NT	120
6	>10000	NT	260
7	NT	NT	2400
8	>10000	NT	10000
9	>10000	NT	3000
10	13000	NT	690
11	NT	NT	10000
12	NT	NT	>30000
13	3600	NT	>30000
14	>10000	NT	10000
15	3110	NT	440
16	NT	NT	>30000
17	NT	NT	>30000
18	NT	NT	>30000
19	258	NT	92
20	5520	NT	10000
21	520	NT	520
23	98.2	NT	64
24	NT	NT	>30000
25	70900	NT	10000
26	28.2	NT	69
27	NT	NT	>30000
28	NT	NT	>30000
29	NT	NT	>30000
30	NT	NT	>30000
31	NT	NT	>30000
32	NT	NT	>30000
33	3.37	NT	25
34	NT	NT	>30000
35	9.64	NT	60
36	45.6	NT	41
37	24.9	NT	16
38a	1.76	NT	12

38b	0.72	NT	NT
38c	3.59	NT	NT
39	0.89	NT	14
40	29.6	NT	195
41	4.58	NT	86
42	1.94	NT	16
43	3.66	NT	20
44	1.96	NT	13
45	1540	NT	511
46	8.81	NT	540
47	1030	NT	3000
48	19.3	NT	230
49	2.66	NT	130
50	1.8	NT	80
51	24	NT	72
52	12.3	NT	250
53	0.48	NT	4.8
54	2.04	NT	5.1
55	1.55	NT	2.3
56	277	NT	200
57	15.4	NT	120
58	2.62	NT	13
59	2.6	NT	9
60	4.99	NT	14
61	3.42	NT	5.7
62	7.59	NT	22
63	16.5	NT	21
64	1.28	NT	22
65	NT	NT	1000
66	1.82	NT	26
67	1.44	NT	390
68	21.3	NT	97
69	2.19	NT	100

70	5.55	NT	460
71	0.84	NT	350
72	7.52	NT	36
73	53.4	NT	110
74	11.3	NT	480
75	NT	NT	730
76	3.81	NT	140
77	6.26	NT	490
79a	10.8	NT	NT
79b	32.3	NT	NT
80a	5.32	NT	NT
80b	25.1	NT	NT
81a	1.12	NT	NT
81b	5.25	NT	NT
82	103	NT	NT
83	15.5	NT	NT
84a	2700	NT	NT
84b	2730	NT	NT
85a	45.4	NT	NT
85b	50.2	NT	NT
86	1.7	NT	NT
87	NT	53.7	NT
88	15.5	1270	NT
89	NT	1080	NT
90	NT	259	NT
91	NT	1480	NT
92	NT	7080	NT
93	3.59	517	NT
94	0.719	131	NT
95	1.7	217	NT
96	50.2	NT	NT
97	45.4	NT	NT
98	2730	100000	NT

99	2700	100000	NT
100	5.25	781	NT
101	1.12	53.1	NT
102	25.1	100000	NT
103	5.32	101	NT
104	32.3	100000	NT
105	10.8	4922	NT
106	8.6	2840	NT
107	0.93	28.7	NT
108	186	NT	NT
109	29.2	100000	NT
110	0.531	185	NT
111	NT	100000	NT
112	NT	100000	NT
113	NT	100000	NT
114	NT	100000	NT
115	NT	100000	NT
116	NT	100000	NT
117	NT	100000	NT
118	2.16	169	NT
119	0.5	152	NT
120	95.7	10000	NT
121	5.75	88.5	NT
122	73	1700	NT
123	NT	NT	NT
124	NT	NT	NT
125	NT	NT	NT
126	NT	NT	NT
127	NT	NT	NT

EXAMPLE 3

Broadly stimulated recombinant
human VR1 and rat VR1 functional assays

When nociceptors are exposed to tissue damaging stimuli, VR1 receptors are activated by a plethora of stimuli. In an effort to identify potent and efficacious antagonists at human and rat VR1 that were active under conditions simulating aspects of in vivo inflammation functional assays were developed using FLIPR to determine antagonist activity against endogenous activators and stimuli likely to be present in inflammation. Cell lines were constructed that stably expressed recombinant rat VR1 (rVR1/HEK293). Cells were exposed to various stimuli at their EC_{80} , with the exception of the low pH and DTT stimuli.

Low pH (pH 5.9 (rat) or pH 6.5 (human)). Cells were challenged for 5 min with low pH solution which produced an increase in intracellular Ca^{2+} which was subsequently reduced by exposure to antagonists. After 3 min, other stimuli (a phorbol ester to induce phosphorylation, capsaicin, anandamide, redox agents) were applied to the cells to determine the potency of antagonists to block those stimuli in an acidic environment. Cells were maintained in low pH in all steps subsequent to the calcium dye loading step.

Phosphorylation by PKC. Previous studies have suggested that phorbol esters activate VR1 via PKC phosphorylation [Premkumar, 2000 #697; Vellani, 2001 #739]. These studies were corroborated and further studies were performed to confirm that the phorbol ester effect was not due to direct effects on the channel. The role of PKC was shown pharmacologically: phorbol-12-myristate-13-acetate (PMA) and other phorbol esters active at PKC (but not the inactive 4α -phorbol) caused an increase in intracellular Ca^{2+} that was mediated by VR1. The rank order potency for the panel of phorbol esters was similar to their rank order potency to block PKC. The PKC inhibitors bisindolylmaleimide (BIM) and staurosporin blocked the PMA induced increase in Ca^{2+} . The EC_{50} for PMA at either rat or human recombinant VR1 was 90 nM. Cells were challenged with 300 nM PMA ($\sim EC_{80}$) after 3 min in the indicated antagonist. The active phorbol ester effect was blocked by RR and CPZ and required extracellular Ca^{2+} . CPZ was more potent at the recombinant human

compared to the rat receptor.

Anandamide. Anandamide is a brain-derived cannabinoid ligand that acts as a near full agonist at VR1 at low μM concentrations [Smart, 2000 #507]. The EC_{50} of anandamide at recombinant rat and human receptors was 5 μM and 3 μM , respectively. The IC_{50} was determined near the EC_{80} of anandamide (10 μM).

Reactive oxygen species: Disturbances in the regulatory activities of free radicals may play a role in inflammation [Winrow, 1993]. Reactive oxygen species (ROS) such as H_2O_2 are formed in inflamed joints. H_2O_2 directly activates VR1: the increase in intracellular Ca^{2+} is in part blocked by VR1 antagonists and the response is dependent on extracellular Ca^{2+} . The influx of Ca^{2+} through VR1 may contribute to the known effects of ROS on signal transduction (e.g., phosphorylation of proteins) and downstream regulation of gene transcription. The EC_{80} for H_2O_2 -induced Ca^{2+} flux in VR1/HEK cells was 0.015% H_2O_2 and this concentration was used to determine the IC_{50} of VR1 antagonists.

Reducing agents: The reducing agent DTT also directly activates VR1 [Vyklícky, 2002]. Cells were challenged with 5-10 mM DTT to stimulate VR1 after 3 min incubation in compound.

Compound 33 potently blocked the activation of human recombinant VR1 elicited by the agonists shown in Table 3. The increase in intracellular Ca^{2+} caused by acidic solutions, anandamide the PKC activator PMA, and H_2O_2 was completely abolished by Compound 33 in a dose dependent manner after 3 min incubation in antagonist (Table 3). The IC_{50} values obtained in assays with low pH, anandamide and PMA stimuli were similar to the IC_{50} values obtained against capsaicin-induced responses. Thus, Compound 33 is a potent antagonist against a panel of activators at the recombinant human receptor, with a more favorable pharmacological profile than the two most well studied antagonists, capsazepine and ruthenium red.

Table 3. Antagonism of recombinant human VR1 activated by a panel of stimuli in a Ca^{2+} influx in vitro assay (IC_{50} in nM)

Compound	Low pH (nM)	Anandamide (nM)	PKC phosphorylation (nM)	PKC phosphorylation at low pH (nM)	H_2O_2 reactive oxygen species (nM)
33	23, 40	41		70	39
Capsazepine (CPZ)	110		160	370	
Ruthenium Red (RR)	500		500		

5 The reference compounds used in these studies were the previously characterized VR1 antagonists capsazepine (CPZ) and ruthenium red. CPZ, previously the most potent antagonist at human VR1, shows similar potency (100-300 nM) at the human recombinant receptor to inhibit Ca^{2+} activity induced by these stimuli (Figure 1, left set of panels). For Figure 1, human (left) and rat (right) vanilloid 1 receptor expressed in HEK 293 cells was stimulated by a number of different stimuli known to activate VR1. Figure 1 shows the IC_{50} values of the competitive vanilloid antagonist capsazepine for inhibition of the calcium flux induced by each of these activators. Note the similar potency of the compound at the human receptor stimulated by various stimuli, but the lower potency of the compound as an inhibitor of rat VR1.

10 In Figure 2, the human (left) and rat (right) vanilloid 1 receptor expressed in HEK 293 cells was stimulated by a number of different stimuli known to activate VR1. The IC_{50} values for inhibition by example #33 of the calcium flux induced by each of these activators is seen in Figure 2.

CPZ has been shown to have significantly lower potency at the rat

receptor (recombinant and native receptors; [McIntyre, 2001]). Since many of our animal models were in rat, we cloned the rat VR1 and expressed it stably in HEK293 cells. We performed assays similar to those described for the human recombinant receptor with the exception that a lower pH was required in the

5 Ca^{2+} influx assay at the rat recombinant receptor.

As expected based on data from the literature, the CPZ profile revealed low potency against heat-induced responses at the recombinant rat receptor [Nagy, 1999]. With the exception of the pore blocker RR, antagonists tended

10 to have a lower potency at the rat compared to the human recombinant receptor. Importantly, Compound 33 potently and completely blocks rat recombinant VR1 activated by acidic solution, anandamide, and H_2O_2 , and PMA at acidic pH (Table 4).

15 **Table 4. Antagonism of recombinant rat VR1 activated by a panel of stimuli in the Ca^{2+} influx in vitro assay (IC_{50} in nM)**

Compound	Low pH (nM)	Anandamide (nM)	PKC phosphorylation (nM)	PKC phosphorylation at low pH (nM)	H_2O_2 (nM)
Cmpd 33	170	38		47	33
Capazepine (CPZ)	500 0	1300	10000	10000	
Ruthenium Red (RR)		1860	300		

Compound 33 potently blocked the activation of rat recombinant VR1 elicited by the agonists shown in Table 4. The increase in intracellular Ca^{2+}

20 caused by acidic solutions, anandamide the PKC activator PMA at low pH, and H_2O_2 was completely abolished by Compound 33 in a dose dependent manner after 3 min incubation in antagonist (Table 4). The IC_{50} values obtained in assays with low pH, anandamide and PMA stimuli were similar to the IC_{50} values obtained against capsaicin-induced responses with the possible

25 exception of the blockade of the low pH response. Thus, Compound 33 is a

potent antagonist against a panel of activators at the recombinant rat receptor, with a more favorable pharmacological profile than the two most well studied antagonists, capsazepine and ruthenium red.

5

EXAMPLE 4

Electrophysiologic functional assay using dissociated rat DRG cells

Compounds 42, 95, 101, 105 and 106 were tested for their activity on
10 VR1 expressed endogenously on small rat dorsal root ganglion (DRG)
neurons. DRG neurons from normal rats were dissociated (see methods in
Chaplan et al., 2003) and whole cell currents mediated by VR1 were recorded
using the whole cell patch clamp technique. The estimated potency of the
compounds were determined either 1) by measuring the shift in the capsaicin-
15 induced dose response in the presence of compound or 2) by calculating the
percent of capsaicin-induced current responses in the presence of compound
under conditions of limited capsaicin-induced desensitization (i.e., using 0
Ca²⁺-containing saline solutions). Under these conditions, repeated application
of capsaicin produced similar current responses when 3 min recovery/washout
20 periods were allowed. Briefly in the first method, if a cell was responsive to
300 nM capsaicin (~ EC₂₀), compound was applied to the cell at 100 or 300 or
1000 nM to determine if the compound had intrinsic agonist activity and allow a
4-5 min incubation period prior to testing with capsaicin in the presence of
compound. After 4-5 min exposure to compound, 1 μM capsaicin was applied
25 in the presence of the same concentration of compound and incubated another
2-3 min. This was followed by application of 10 μM CAP in the presence of
compound. Control cumulative capsaicin dose response curves (filled
squares) were obtained from a cell (the approximate EC₅₀ in this cumulative
dose response assay was ~1 μM CAP; 10 μM causes a maximal response).
30 Vehicle caused no shift in the capsaicin concentration dependence (not
shown). The ability of 1 and 10 μM CAP to cause an increased current after
exposure to a compound of the invention was compared to controls.

In the second method, a nociceptor was challenged with 0.3 μ M capsaicin while taking measurements of whole cell current using voltage ramp protocols. After washout of the capsaicin, cells were exposed to the compound for 4-5 min and subsequently challenged with 1 μ M capsaicin (approximately the ED80 at the native receptor in this experiments) in the continued presence of compound. The current elicited near -100 mV was measured during the first and second capsaicin exposure. The percent of the response elicited by 0.3 μ M capsaicin obtained during the exposure to 1 μ M capsaicin/compound was calculated. After washout, the cell was challenged with 10 μ M capsaicin in the presence of compound and subsequently washed again and challenged with capsaicin without compound.

Table 5. VR1 antagonists inhibit capsaicin-induced currents in dissociated rat DRG neurons

Compound	Compound concentration (μ M)	% of the initial CAP response in presence of 1 μ M CAP	% of the initial CAP response in presence of 10 μ M CAP
42	0.3	0	
95	0.03	78	1073
	0.1	21	200
	0.1	4	12
101	0.03	14	54
	0.1	0	0
105	1	0	23
		8	160
106	1	2	11
vehicle		330	
		115	180
		171	204

All compounds inhibited the response to 1 μ M capsaicin. The inhibition was dose dependent (compounds 95 and 101). The response to 10 μ M

capsaicin in the presence of compound was larger than the response to 1 μ M capsaicin/compound with the exception of the cell challenged with 0.1 μ M 101 which revealed no capsaicin induced current until the compound was washed out and capsaicin alone was applied to the cell. These results indicate that

5 Compounds 95 and 101 appeared to shift the capsaicin dose response to the right in a dose dependent manner. PKB' values could not be determined because it is not known whether the blockade could not be surmounted by higher concentrations of capsaicin. Tested compounds had no detectable, reproducible effect on whole cell voltage-activated currents in the DRG

10 neurons studied.

EXAMPLE 5

Carrageenan paw-induced thermal hyperalgesia

15 Each rat was placed on a heated surface (51°C) in order to measure the time necessary to elicit a response, and an initial (baseline) response time to a thermal stimuli was recorded for each animal. A response is defined as any shaking, licking, or tucking of the treated paw or jumping. Animals not treated with a test compound respond in approximately 20 seconds. The maximal

20 exposure time permitted is 60 seconds to prevent tissue damage. Rats were injected with an irritant (e.g., 1% carrageenan solution in 0.9% saline) subcutaneously into the sub-plantar tissue of the left hind paw to stimulate an acute inflammatory reaction.

Two hours later, the response time of the animal to the thermal stimulus

25 was evaluated and compared to the animal's baseline response time. This shorter response time was recorded as percent hyperalgesia (%H). A cut-off value for %H (usually 75%) was used during analysis to ensure that the animals were hyperalgesic. Animals were then dosed with test drug or vehicle.

At some time(s) later (typically 45 and 90 minutes), the response time of

30 the animal to the thermal stimulus was again evaluated. For each time point, a percent reversal of hyperalgesia (%R) was calculated using the following formula: $\%R = (\text{Drug Latency} - \text{Carrageenan latency}) / (\text{Baseline latency} - \text{Carrageenan latency})$. ED₅₀ values were calculated from %R obtained at

several drug doses.

Cmpd No	CgHP ED ₅₀ (mg/kg, po)
33	0.276
57	0.354
4	0.804
17	19.958

5 Table 6. Percent Recovery at 1 mg/ml or ED₅₀ value (mg/kg, p.o.), each at 90 min.

Compound	% Recovery	ED ₅₀ (mg/kg, p.o.)
106		0.027
105		0.394
107		0.92
110	64.3	
120	83.0	
121	80.1	
124	55.2	
125	63.9	
126	46.0	
127	41.3	

EXAMPLE 6

10 Evaluation of action on isolated guinea pig bronchial rings

Aminotetralin VR1 antagonists were tested for their potency to block capsaicin-induced guinea pig bronchial ring contraction in a standard in vitro organ bath assay [Tucker, 2001]. Two mm rings of bronchial tissue obtained

from male guinea pigs (325 g) were suspended in normal Krebs solution between two wire hooks under an initial loading tension of 1 gram. The saline was maintained in a 5% CO₂ and 95% O₂ atmosphere at 37°C in the presence of indomethacin (5 µM). A sub-maximal dose of 5-Methylfurmethide (5Mef, 1 µM) was added to each tissue to determine responsiveness using an isometric force transducer. After washout, tissues were exposed to compounds or vehicle for 30 min, treated with thiorphan (10 µM, 5% Na₂CO₃), and primed using KCl in increasing linear concentrations from 1mM at 1mM intervals until a slight increase in muscle tone was induced (~1% of 5Mef response). A concentration-response curve was then constructed using capsaicin (10nM - 10µM) increasing in 0.5 log unit increments. The dose response curve was calculated as % max of the 5-Mef response and estimated pA₂ were determined [Tucker, 2001]).

Both Compound 38a (Figure 3) and Compound 105 (Figure 4) inhibited capsaicin-evoked bronchial ring contraction with an estimated pA₂ of 8.0 and 6.2, respectively (Table 7). The potent antagonism of capsaicin-induced bronchial ring contraction indicated that these compounds may be effective inhibitors of cough and bronchial spasm mediated by VR1.

In Figure 3, inhibition of capsaicin-induced contraction of guinea pig bronchial rings is shown for an isolated tissue assay. The closed symbols represent the capsaicin-only concentration-response relationship, whereas the open symbols represent the capsaicin plus example number 105 concentration-response. The inhibition appears as a shift to the right of the concentration-response curve, resulting in a pA₂ (±SEM) value of 6.2±0.11.

In Figure 4, inhibition of capsaicin-induced contraction of guinea pig bronchial rings is shown for an isolated tissue assay. The closed symbols represent the capsaicin-only concentration-response relationship, whereas the open symbols represent the capsaicin plus example number 38a concentration-response. The inhibition appears as a shift to the right of the concentration-response curve, resulting in a pA₂ (±SEM) value of 8.0±0.02.

Table 7. VR1 antagonist blocked capsaicin-induced guinea pig bronchial

ring contraction in a competitive manner.

Compound	Estimated pA ₂
33	8.0 +/- 0.02
105 (1000 nM)	6.2 +/- 0.11

EXAMPLE 7

5 Antitussive efficacy of VR1 antagonists

The antitussive activity of intraperitoneally (IP) administered compound is assessed at a single dose level against capsaicin-induced cough responses as compared to positive and vehicle controls. Thirty-six male Dunkin-Hartley
10 guinea pigs (295-590g, mean = 425 g) are randomly allocated to one of three groups (n=12 guinea pigs per group). The blinding code is not revealed to the experimenter until coughs from all animals are tallied. Guinea pigs are dosed IP at -60min with vehicle (15% Solutol in 5% dextrose solution); the positive control codeine (25mg/kg), or test compound (20mg/kg in 15% Solutol in 5%
15 dextrose solution). Individual guinea pigs are placed in an exposure chamber with an airflow of 3 L/min at -10min to acclimatize. At ± 0 min, cough responses are induced by exposure to capsaicin aerosol (15 μ M) generated by an ultrasonic nebulizer at a nebulization rate of 0.6ml/min for 4 min. Coughs are counted throughout the 4 min capsaicin exposure and for a further 11 min.
20 The mean \pm SEM number of capsaicin-induced cough responses recorded in vehicle pre-treated guinea pigs was 3.0 ± 0.5 . This level of response was reduced significantly to 0.58 ± 0.15 coughs in codeine pre-treated guinea pigs ($P < 0.001$) and is reduced in compound pre-treated guinea pigs. ANOVA statistical analysis was used to determine the level of significance.

25

The antitussive properties of test compounds are assessed in a citric acid-induced cough model as compared to positive and vehicle controls. Evaluation of a given compound in this paradigm is as follows: Six male Dunkin-Hartley guinea pigs (approximately 300-600 g) are randomly assigned

to each treatment group. Guinea pigs are intra-peritoneally (IP) injected with vehicle, test compound, or positive control (codeine 25 mg/kg) 60 minutes prior to citric acid exposure. Individual guinea pigs are placed in an exposure chamber with an airflow of 3 L/min at -10min to acclimatize. At ± 0 min, cough
5 responses are induced by exposure to nebulized citric acid. Coughs elicited during the 10-minute aerosol of citric acid and additional 5-minute observation period are recorded and analysed for onset of cough, and cough number and frequency. To eliminate bias, pre-treatments are randomised and the experiments are done blinded. The blinding code is not revealed to the
10 experimenter until coughs from all animals are tallied.

EXAMPLE 8

Rodent Colitis Model

15 5% Dextran Sulfate Sodium administered in the drinking water of mice or rats for 7 days results in an acute colitis with some morphological changes that are similar to human ulcerative colitis. Among those changes are colon shortening, accumulation of neutrophils and other inflammatory cells, decreases in colon weight, decreases in body weight, tissue damage in the
20 colon, and loss of stool consistency.

Each animal is dosed daily in the morning and late afternoon for BID dosing. Treatment with vehicle or test compound begins on day 0, immediately after initial body weights are taken, and ends on day 6. Water bottles are removed and replaced by graduated water bottles containing 5% DSS in
25 indicated groups. Tap water remains on control groups only. Sufficient DSS drinking water is placed in graduated water bottles and refilled each day to monitor daily output. Animals are weighed daily from day 0 to 7, and animal condition and the consistency of stools recorded. Following sacrifice of the animal on day 7, the colon is surgically removed from the distal rectum (anus)
30 to the cecal-colonic juncture and the colon length and weight measured. Colon slices may be obtained for histological evaluation. An active drug should decrease or eliminate disruption of the epithelium and colonic folds, dense inflammatory cell infiltrates, mucosal sloughing, etc. In life observations

include monitoring for signs of gross toxicity and/or behavioral changes, gross evaluation of the skin and fur, motor activity and any behavioral patterns with special attention to tremors, convulsions and diarrhea. Water consumption and body weights are measured daily. Scores include ratings for colon weight
5 loss, stool consistency, colon damage, and colon shortening, and are used to assemble a Disease Activity Score. An increase in myeloperoxidase activity occurs in this model and is evaluated separately.

EXAMPLE 9

10

Uterine pain assessment

Female adult virgin Sprague Dawley rats (190-290 g) are used. Rats are anesthetized with pentobarbital (50 mg/kg IP). One uterine horn is approached via a small ventral midline laparotomy and tightly ligated at its
15 caudal end near the cervix with 3.0 silk suture to prevent leakage of mustard oil through the cervix and vagina. Using a 22G needle 0.1-0.2 ml of 10% mustard oil (Aldrich Chemical Co., Milwaukee WI USA; dissolved in mineral oil) or an equivalent volume of saline in sham control rats, are injected into the uterine lumen. The abdominal incision is then closed and the rats allowed to recover
20 from anesthesia. Rats are then transferred to individual Plexiglas cages in a quiet environment (12/12 h light-dark cycle) with food and water ad libitum for nonstop videotape recording for the duration of the experiment. Compounds or vehicle is administered by the intended route before (therapeutic) or after (prophylactic) acquisition of hyperalgesia. The recording system consists of a
25 camera connected to a videotape recorder with a wide range of recording and reading speeds to allow for detailed analysis of the movements of the rats. During the dark phase an infrared light is used to permit continuous filming. Animal behavior is analyzed post-hoc using a scoring system to count abnormal behaviors. Six characteristic abnormal behaviors are expected in
30 uterine inflammation rats: (1) hunching (2) hump-backed position (3) repeated licking of the lower abdomen/ipsilateral flank (4) repeated waves of contraction of the ipsilateral oblique musculature with inward turning of the ipsilateral hind limb (5) stretching of the body (6) squashing of the lower abdomen against the

cage floor. The effect of administered compounds on the intensity and frequency of pain related behaviors is quantitatively assessed.

EXAMPLE 10

- 5 Models of itch, contact dermatitis, eczema and other manifestations of dermal allergy, hypersensitivity and/or inflammation

Vanilloid receptor modulators are tested in an animal model of contact dermatitis or itch, according to previously documented and validated methods, including but not limited to those described by Saint-Mezard et al. (2003), Gonzalez et al. (2001), Wille et al. (1998), Weisshaar et al. (1999) and Thomsen et al. (2002). In models of contact dermatitis, testing is conducted in mouse, guinea pig or human in response to a single (primary allergic dermatitis) or repeated (sensitized allergic dermatitis) topical or photomechanical exposure of the skin to one or more haptens selected from 12-myristate-13 acetate, picryl chloride, oxazolone, capsaicin, arachidonic acid, lactic acid, trans-retinoic acid or sodium lauryl sulfate. For increased sensitivity, animals are sensitized by pre-exposure to certain agents selected from dinitrochlorobenzene, para-phenylenediamine or oxazolone. For prophylactic or therapeutic testing, a vanilloid receptor modulator or vehicle control is administered to the test subjects by the enteral or parenteral route prior to or following hapten challenge. Significant differences in skin inflammation (erythema, edema, hyperthermia, etc.) for the test compound-treated subjects compared with vehicle-treated subjects demonstrate anti-allergy activity. The following additional dependent measures are also collected and compared: skin and/or lymph node levels of CF8+ T cells, interleukin-1 alpha and beta, tumor necrosis factor alpha, interferon gamma, nitric oxide, inducible nitric oxide synthase and keratinocyte apoptosis, Fas expression and/or inflammatory mediator secretion.

30 In models of itch, testing is conducted in mouse, rat, guinea pig or human in response to the sub- or intra-dermal injection or iontophoresis of pruritogens selected from serotonin, compound 48/80, leukotriene B4, arachidonic acid, prostaglandin E2, histamine, substance P, neurokinin A,

neurokinin B, trypsin, hydroxyethylstarch or platelet-activating factor singly or in combination with mosquito bite or injection of salivary gland extract therefrom. In some cases, animals are inflamed by pre-exposure to certain agents, including but not limited to sodium lauryl sulfate. For prophylactic or
5 therapeutic testing, a vanilloid receptor modulator or vehicle control is administered to the test subjects by the enteral or parenteral route prior to or following pruritogen challenge. Cumulative scratching behavior and/or number of scratches per unit time are measured. Significant differences in scratching behavior for the test compound-treated subjects compared with vehicle-treated
10 subjects demonstrate anti-pruritic activity. The following additional dependent measures are collected and compared: skin inflammation (erythema, edema, hyperthermia, etc.), surface area of the wheal and flare, hyperalgesia, allodynia, plasma protein extravasation, inflammatory mediator release and serum immunoglobulin levels.

15

EXAMPLE 11

Models of rhinitis and other manifestations of nasal
20 hypersensitivity and/or inflammation

Vanilloid receptor modulators are tested in an animal model of rhinitis, according to previously documented and validated methods, including but not limited to those described by Hirayama et al. (2003), Tiniakov et al. (2003) and
25 Magyar et al. (2002). Testing is conducted in mouse, guinea pig, dog or human in response to intranasal challenge with one or more irritants selected from bradykinin, histamine, pollens, dextran sulfate, 2,4-tolylene diisocyanate, Bordetella bronchiseptica, Pasteurella multodica or acetic acid. For increased sensitivity, animals may be sensitized by pre-exposure to ragweed or
30 ovalbumin. For prophylactic or therapeutic testing, a vanilloid receptor modulator or vehicle control is administered to the test subjects by the enteral or parenteral route prior to or following irritant challenge. The relevant dependent measures collected are plasma extravasation of the nasal mucosa,

nasal eosinophilia or neutrophilia, nasal mucosal or nasal cavity lavage fluid levels of IL-5, interferon gamma, histamine or IgE, serum immunoglobulin levels, rhinorrhea, cumulative time spent sneezing or number of sneezes per unit time, nasal airway volume, peak inspiratory flow and resistance, intranasal
5 pressure and nasal lesions. Significant differences in one or more of these measures for the test compound-treated subjects compared with vehicle-treated subjects demonstrate anti-rhinitis activity.


EXAMPLE 12

10 Models of anxiety, panic disorder and other non-adaptive stressful or phobic responses

Vanilloid receptor modulators are tested in an animal model of anxiety, according to previously documented and validated methods, including but not
15 limited to those reviewed by Imaizumi and Onodera (2000). Testing is conducted in mouse or rat and consists of methods to measure avoidance of aversive environmental stimuli selected from the Geller-type or Vogel-type anticonflict tests, the light/dark test, the hole-board test, the elevated plus-maze and the elevated T-maze. Prior to environmental exposure the test subject
20 receives the prophylactic administration one or more times of a vanilloid receptor modulator, or vehicle control, by the enteral or parenteral route. The cumulative time or number of times spent engaged in the aversive behavior is measured. Significant differences in one or more of these measures for the test compound-treated subjects compared with vehicle-treated subjects are
25 taken as evidence of anxiolytic activity.

Claims:

1. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

- R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C_{1-8} alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C_{1-8} alkanyl)carbonyl;
- n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R_2 is independently selected from the group consisting of hydrogen;


hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

- R_4 is selected from the group consisting of hydrogen and C_{1-8} alkanyl;
- R_5 is selected from the group consisting of hydrogen and C_{1-8} alkanyl;
- 5 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

2. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

- R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C_{1-8} alkanyloxy;
- 15 n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R_2 is independently selected from the group consisting of hydrogen; hydroxy; C_{1-8} alkanyl; C_{2-8} alkenyl; C_{1-8} alkylidenyl; C_{1-8} alkylidynyl; fluoro; chloro; C_{3-8} cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy, phenyl(C_{1-8})alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C_{1-8} alkanylamino, and C_{1-8} dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C_{1-8} alkanyl, C_{1-8} alkanyloxy, phenyl(C_{1-8})alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C_{1-8} alkanylamino, and C_{1-8} dialkanylamino; phenoxy optionally substituted with one to three substituents
- 20
- 25

- independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- 5 L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinoliny, quinoliny-N-oxide, isoquinoliny, isoquinoliny-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;
- 10 R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
- 15 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
- 20 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
- 25 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
- 30 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

3. The composition of claim 2 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three

substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl.


10

4. The composition of claim 2 wherein L is a direct bond or C₁₋₈alkandiyl.

5. The composition of claim 2 wherein R₃ is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyl-N-oxide.

20

6. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally


25

- substituted with one or more substituents independently selected from the group consisting of halogen; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy,

- hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, 5 fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, 10 isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide pyrimidyl, furyl, thienyl or imidazolyl;
- R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- R₅ is selected from the group consisting of hydrogen and 15 C₁₋₈alkanyl;
- X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
- 20 7. The composition of claim 6 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.
8. The composition of claim 6 wherein R₁ is a substituent 25 independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.
9. The composition of claim 6 wherein L is a direct bond or C₁₋₈alkandiyl.
- 30 10. The composition of claim 6 wherein R₃ is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with one or more

substituents selected from the group consisting of methyl and chloro; and isoquinoliny-N-oxide.

11. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

- R₁** is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- n** is an integer from 1 to 3;
- m** is an integer from 0 to 3;
- R₂** is independently selected from the group consisting of hydrogen;


- C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl;
 phenyl optionally substituted with one to three substituents
 independently selected from the group consisting of fluoro,
 chloro, bromo, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy and
 5 fluorinated alkanyl; naphthyl optionally substituted with one to
 three substituents independently selected from the group
 consisting of fluoro, chloro, bromo, C₁₋₈alkanyloxy,
 phenyl(C₁₋₈)alkanyloxy and fluorinated alkanyl; pyridyl; pyrimidyl;
 furyl; thienyl and imidazolyl;
- 10 L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or
 C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of phenyl optionally
 substituted with one to three substituents independently selected
 from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy,
 15 hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
 C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with
 one to three substituents independently selected from the group
 consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy,
 fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
 20 C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted
 with one to three substituents independently selected from the
 group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano
 wherein said heteroaryl is quinoliny, quinoliny-N-oxide,
 isoquinoliny, isoquinoliny-N-oxide, pyridyl, pyridyl-N-oxide,
 25 pyrimidyl, furyl, thienyl or imidazolyl;
- R₄ is selected from the group consisting of hydrogen and
 C₁₋₈alkanyl;
- R₅ is selected from the group consisting of hydrogen and
 C₁₋₈alkanyl;
- 30 X is selected from the group consisting of O and S; and
 enantiomers, diastereomers, tautomers, solvates, and pharmaceutically
 acceptable salts thereof.

12. The composition of claim 11 wherein R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C_{1-8} alkanyloxy.

5 13. The composition of claim 11 wherein L is a direct bond or C_{1-8} alkandiyl.

14. The composition of claim 11 wherein R_3 is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyl-N-oxide.

15 15. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy;

- 5 C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino;
C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino;
cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy;
formyl; carbamoyl; phenyl optionally substituted with one to three
substituents independently selected from the group consisting of
halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl;
amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and
aryl(C₁₋₈alkanyl)carbonyl;
- 10 n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- 15 R₂ is independently selected from the group consisting of
C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl;
phenyl optionally substituted with one to three substituents
independently selected from the group consisting of fluoro,
chloro, bromo, and fluorinated alkanyl;
- 20 L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or
C₃₋₈cycloalkandiyl;
- 25 R₃ is selected from the group consisting of phenyl optionally
substituted with one to three substituents independently selected
from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy,
hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with
one to three substituents independently selected from the group
consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy,
fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted
with one to three substituents independently selected from the
group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano
wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide,
isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide,
pyrimidyl, furyl, thienyl or imidazolyl;
- 30 R₄ is selected from the group consisting of hydrogen and
C₁₋₈alkanyl;

- R_5 is selected from the group consisting of hydrogen and C_{1-8} alkanyl;
 X is selected from the group consisting of O and S; and
 5 acceptable salts thereof.

16. The composition of claim 15 wherein R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C_{1-8} alkanyloxy.

10

17. The composition of claim 15 wherein R_1 is a substituent independently selected from the group consisting of fluoro; chloro; and C_{1-8} alkanyloxy.


15

18. The composition of claim 15 wherein L is a direct bond or C_{1-8} alkandiyl.

19. The composition of claim 15 wherein R_3 is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyl-N-oxide.

25

20. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

R_1 is a substituent independently selected from the group consisting

- of fluoro; chloro; C₁₋₈alkanyloxy;
- n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen;
 5 hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl;
 fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with
 one to three substituents independently selected from the group
 consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy,
 10 phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino,
 C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally
 substituted with one to three substituents independently selected
 from the group consisting of halogen, hydroxy, C₁₋₈alkanyl,
 C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano,
 15 nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy
 optionally substituted with one to three substituents
 independently selected from the group consisting of halogen,
 hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano
 and nitro; and heteroaryl optionally substituted with one to three
 substituents independently selected from the group consisting of
 20 C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl,
 pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or
 C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of phenyl optionally
 25 substituted with one to three substituents independently selected
 from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy,
 hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
 C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with
 one to three substituents independently selected from the group
 30 consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy,
 fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
 C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted
 with one to three substituents independently selected from the

group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

5 R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

 X is selected from the group consisting of O and S; and
10 enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

21. The composition of claim 20 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl;
15 C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro,
20 bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl.


25

22. The composition of claim 20 wherein L is a direct bond or C₁₋₈alkandiyl.

23. The composition of claim 20 wherein R₃ is selected from the
30 group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and

chloro and isoquinolinyl-N-oxide.

24. A compos
25. ition comprising a compound of Formula (I):



Formula (I)

wherein:

- R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C_{1-8} alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C_{1-8} alkanyl)carbonyl;
- n is 1;
- m is an integer from 0 to 3;
- R_2 is independently selected from the group consisting of hydrogen;

hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

5 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

25. The composition of claim 24 wherein R₁ is a substituent
10 independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.

26. The composition of claim 24 wherein R₁ is a substituent
15 independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.


27. The composition of claim 24 wherein R₂ is independently
selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl;
C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three
20 substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three
substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and
25 fluorinated alkanyl; and a heteroaryl optionally substituted with one to three
substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl.

30 28. The composition of claim 24 wherein L is a direct bond or C₁₋₈alkandiyl.

29. The composition of claim 24 wherein R₃ is selected from the

group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyl-N-oxide.

30. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

10 R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally

15 independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group

20 consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three

25 substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C_{1-8} alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C_{1-8} alkanyl)carbonyl;

- n is an integer from 1 to 3;
- m is an integer from 0 to 1;
- R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano

wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

5 R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

31. The composition of claim 30 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.

15

32. The composition of claim 30 wherein R₁ is a substituent independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.

20 33. The composition of claim 30 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl.


25

34. The composition of claim 30 wherein L is a direct bond

or C₁₋₈alkandiyl.

35. The composition of claim 30 wherein R₃ is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyl-N-oxide.

36. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

- R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of

- halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- 5 n is an integer from 1 to 3;
- m is 1;
- R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group
- 10 consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl,
- 15 C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen,
- 20 hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or
- 25 C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
- 30 C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,

5 C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

10 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

15 37. The composition of claim 36 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.


20 38. The composition of claim 36 wherein R₁ is a substituent independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.

25 39. The composition of claim 36 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and 30 a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl.

40. The composition of claim 36 wherein L is a direct bond or C₁₋₈alkandiyl.

5 41. The composition of claim 36 wherein R₃ is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with
10 chloro and isoquinolinyl-N-oxide.

42. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

15 R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally
20 independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group
25 consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy;

- formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- 5 n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl;
- 10 fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally
- 15 substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents
- 20 independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl,
- 25 pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond or C₁₋₈alkandiyl;
- R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
- 30 C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy,

fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano
5 wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;
R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
10 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

15

43. The composition of claim 42 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.

20

44. The composition of claim 42 wherein R₁ is a substituent independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.

25


45. The composition of claim 42 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three
30 substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl

and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl.

46. The composition of claim 42 wherein R_3 is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyl-N-oxide.

10

47. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

- R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three

- substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- 5 n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with
- 10 one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected
- 15 from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents
- independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano
- 20 and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- 25 L is a direct bond;
- R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
- 30 C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,

5 C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

10 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

15 48. The composition of claim 47 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.

20 49. The composition of claim 47 wherein R₁ is a substituent independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.


25 50. The composition of claim 47 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or

30

imidazolyl.

51. The composition of claim 47 wherein R_3 is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyln optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyln-N-oxide; isoquinolinyln optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyln-N-oxide.

52. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

- R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of

- halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- 5 n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group
- 10 consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl,
- 15 C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen,
- 20 hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or
- 25 C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, fluoro, chloro, bromo, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl substituted with one to
- 30 three substituents independently selected from the group consisting of C₁₋₈alkanyl, fluoro, chloro, bromo, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,

5 C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, fluoro and chloro, wherein said heteroaryl is quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

10 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

15 53. The composition of claim 52 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.

20 54. The composition of claim 52 wherein R₁ is a substituent independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.

25 55. The composition of claim 52 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or


30

imidazolyl.

56. The composition of claim 52 wherein L is a direct bond or C₁₋₈alkandiyl.

5

57. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

10 **R₁** is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally independently substituted with one or more substituents

15 independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;

20 C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of

25 halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;

n is an integer from 1 to 3;

- m is an integer from 0 to 3;
- 5 R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- 10 15 20 L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;
- 25 R₃ is selected from the group consisting of phenyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyloxy and hydroxy; naphthyl substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyloxy and hydroxy; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl and chloro wherein said heteroaryl is quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl and pyridyl-N-oxide;
- 30 R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- R₅ is selected from the group consisting of hydrogen and

C₁₋₈alkanyl;

X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

5

58. The composition of claim 57 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.

10

59. The composition of claim 57 wherein R₁ is a substituent independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.

15

60. The composition of claim 57 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl.


20

25

61. The composition of claim 57 wherein L is a direct bond or C₁₋₈alkandiyl.

30

62. A composition comprising a compound of Formula (I):

**Formula (I)**

wherein:

- R₁** is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- n** is an integer from 1 to 3;
- m** is an integer from 0 to 3;
- R₂** is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy,

- phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro, quinolinyl-N-oxide, isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyl-N-oxide;
- R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

63. The composition of claim 62 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.


64. The composition of claim 62 wherein R₁ is a substituent

independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.

65. The composition of claim 62 wherein R₂ is independently
 5 selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three
 10 substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or
 15 imidazolyl.

66. The composition of claim 62 wherein L is a direct bond or C₁₋₈alkandiyl.

- 20 67. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

- R₁ is a substituent independently selected from the group consisting
 of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally
 25 independently substituted with one or more substituents
 independently selected from the group consisting of halogen,
 fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally
 independently substituted with one or more substituents

- independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;
- R₃ is 2-hydroxynaphth-8-yl, isoquinolin-5-yl and isoquinolinyl-5-yl-N-oxide;
- 5 R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
- X is selected from the group consisting of O and S; and
- 10 enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

68. The composition of claim 67 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro;

15 chloro; and C₁₋₈alkanyloxy.

69. The composition of claim 67 wherein R₁ is a substituent independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.

20


70. The composition of claim 67 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro,

25 bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three

30 substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl.

71. The composition of claim 67 wherein L is a direct bond or C₁₋₈alkandiyl.

72. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

- R₁** is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- n** is an integer from 1 to 3;
- m** is an integer from 0 to 3;
- R₂** is independently selected from the group consisting of hydrogen;

hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;

L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;

R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

- R₄ is hydrogen;
R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;
X is selected from the group consisting of O and S; and
5 enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

73. The composition of claim 72 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro;
10 chloro; and C₁₋₈alkanyloxy.

74. The composition of claim 72 wherein R₁ is a substituent independently selected from the group consisting of fluoro; chloro; and
15 C₁₋₈alkanyloxy.

75. The composition of claim 72 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro,
20 bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three
25 substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl.


76. The composition of claim 72 wherein L is a direct bond
30 or C₁₋₈alkandiyl.

77. The composition of claim 72 wherein R₃ is selected from the group consisting of naphthyl substituted with hydroxyl; quinoliny optionally

substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyl-N-oxide.

5

78. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

10 R_1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C_{1-8} alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{1-8} alkanyloxy optionally independently substituted with one or more substituents

15 independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C_{1-8} alkanylthio optionally substituted with one

20 or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C_{1-8} alkanyloxy; C_{3-8} cycloalkanyl; C_{3-8} cycloalkanyloxy; nitro; amino; C_{1-8} alkanylamino; C_{1-8} dialkanylamino; C_{3-8} cycloalkanylamino; cyano; carboxy; C_{1-7} alkanyloxycarbonyl; C_{1-7} alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three

25 substituents independently selected from the group consisting of halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C_{1-8} alkanylamino)carbonyl; (arylamino)carbonyl and

- aryl(C₁₋₈alkanyl)carbonyl;
- n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen;
- 5 hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino,
- 10 C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy
- 15 optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of
- 20 C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of phenyl optionally
- 25 substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group
- 30 consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino, C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the

group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

5 R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

 R₅ is hydrogen;

 X is selected from the group consisting of O and S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically

10 acceptable salts thereof.

79. The composition of claim 78 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.

15

80. The composition of claim 78 wherein R₁ is a substituent independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.

20 81. The composition of claim 78 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and

25 fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl


30 and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl.

82. The composition of claim 78 wherein L is a direct bond

or C₁₋₈alkandiyl.

83. The composition of claim 78 wherein R₃ is selected from the group consisting of naphthyl substituted with hydroxyl; quinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinolinyl-N-oxide; isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinolinyl-N-oxide.

84. A composition comprising a compound of Formula (I):



Formula (I)

wherein:

- R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₁₋₈alkanyloxy optionally independently substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C₁₋₈alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy; nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino; C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl; C₁₋₇alkanylcarbonyloxy; formyl; carbamoyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of

- halogen, hydroxyl, nitro, amino and cyano; aroyl; carbamoyl; amidino; (C₁₋₈alkanylamino)carbonyl; (arylamino)carbonyl and aryl(C₁₋₈alkanyl)carbonyl;
- 5 n is an integer from 1 to 3;
- m is an integer from 0 to 3;
- R₂ is independently selected from the group consisting of hydrogen; hydroxy; C₁₋₈alkanyl; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; fluoro; chloro; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group
- 10 consisting of halogen, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₈alkanyl,
- 15 C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, fluorinated alkanyl, cyano, nitro, amino, C₁₋₈alkanylamino, and C₁₋₈dialkanylamino; phenoxy optionally substituted with one to three substituents independently selected from the group consisting of halogen,
- 20 hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, fluorinated alkanyl, cyano and nitro; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or imidazolyl; pyrrolidino; and piperidino;
- L is a direct bond, C₁₋₈alkandiyl, C₂₋₈alkendiyl, C₂₋₈alkyndiyl, or
- 25 C₃₋₈cycloalkandiyl;
- R₃ is selected from the group consisting of phenyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,
- 30 C₁₋₈alkanylamino and cyano; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, nitro, amino, di(C₁₋₈)alkanylamino,

5 C₁₋₈alkanylamino and cyano; and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₈alkanyl, halogen, nitro, amino and cyano wherein said heteroaryl is quinolinyl, quinolinyl-N-oxide, isoquinolinyl, isoquinolinyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrimidyl, furyl, thienyl or imidazolyl;

R₄ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

10 R₅ is selected from the group consisting of hydrogen and C₁₋₈alkanyl;

X is O; and

enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

15 85. The composition of claim 84 wherein R₁ is a substituent independently selected from the group consisting of hydrogen; hydroxy; fluoro; chloro; and C₁₋₈alkanyloxy.

20 86. The composition of claim 84 wherein R₁ is a substituent independently selected from the group consisting of fluoro; chloro; and C₁₋₈alkanyloxy.

25 87. The composition of claim 84 wherein R₂ is independently selected from the group consisting of hydrogen; C₂₋₈alkenyl; C₁₋₈alkylidenyl; C₁₋₈alkylidynyl; C₃₋₈cycloalkanyl; phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; naphthyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, hydroxy, C₁₋₈alkanyl, C₁₋₈alkanyloxy, phenyl(C₁₋₈)alkanyloxy, and fluorinated alkanyl; and a heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkanyl and halogen wherein said heteroaryl is pyridyl, pyrimidyl, furyl, thienyl or

30

imidazolyl.


88. The composition of claim 84 wherein L is a direct bond or C₁₋₈alkandiyl.

5

89. The composition of claim 84 wherein R₃ is selected from the group consisting of naphthyl substituted with hydroxyl; quinoliny optionally substituted with one or more substituents selected from the group consisting of methyl and chloro; quinoliny-N-oxide; isoquinoliny optionally substituted with one or more substituents selected from the group consisting of methyl and chloro and isoquinoliny-N-oxide.

10

90. A composition comprising a compound of Formula (Ia):



Formula (Ia)

- 15 said compound selected from the group consisting of
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 3-Pyridinyl, m is 1, L is -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
 - a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is H, m is 0, L is -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
 - 20 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is Ph, m is 1, L is -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
 - a compound of formula (Ia) wherein R₁ is H, R₂ is 3-Pyridinyl, m is 1, L is -CH₂-, R₃ is (3-OMe-4-(Methoxymethyleneoxy)Ph, and X is S;
 - a compound of formula (Ia) wherein R₁ is H, R₂ is 3-Pyridinyl, m is 1, L is -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
 - 25 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is 3-Pyridinyl, m is 1, L is -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is $-\text{CH}=\text{CH}_2$, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-(Methoxymethyleneoxy)Ph, and X is S;
- 5 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is 4-Imidazolyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-methylenedioxy)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-diOMe)Ph, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (4-*t*Bu)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (4-Cl)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (3,4-diOMe)Ph, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-methylenedioxy)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-diOMe)Ph, and X is S;
- 20 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (4-*t*Bu)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (4-Cl)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (3,4-diOMe)Ph, and X is S;
- 25 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}=\text{CH}-()$, R_3 is (3-OMe-4-OH)Ph, and X is O;
- 30 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-(Methoxymethyleneoxy)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is $(4-\text{N}(\text{Me})(\text{C}_5\text{H}_{11}))\text{Ph}$, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is $(4-[\text{N}(\text{Me})(\text{cyclohexyl})])\text{Ph}$, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-diOMe)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is $(4-\text{CF}_3)\text{Ph}$, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-diCl)Ph, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (3,4-diCl)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is $(4-\text{CF}_3)\text{Ph}$, and X is S;
- 15 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-diCl)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2\text{CH}_2-$, R_3 is (3,4-diCl)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-quinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 8-(2-naphtholyl), and X is O;
- 25 a compound of formula (Ia) wherein R_1 is H, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 30 a compound of formula (Ia) wherein R_1 is 6-Br, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6,7-diOMe, R_2 is Ph, m is 1,

- L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 7-Cl, R₂ is Ph, m is 1, L is a
direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 5-Cl, R₂ is Ph, m is 1, L is a
5 direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is a
direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (3-Cl)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
10 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is 3-Pyridinyl, m is
1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (3-Cl)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is 3-Pyridinyl, m is
15 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6,7-diOMe, R₂ is Ph, m is 1,
L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (2-Cl)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
20 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-Cl)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is H, m is 0, L is
a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (2-Cl)Ph, m is
25 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (2-CF₃)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (3-CF₃)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
30 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-CF₃)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OH, R₂ is Ph, m is 1, L is
a direct bond, R₃ is 5-isoquinolinyl, and X is O;

- a compound of formula (Ia) wherein R_1 is H, R_2 is $-\text{CH}=\text{CH}_2$, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-Br, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 7-Cl, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 8-Cl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-CN)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-Br)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is CN, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6,7-diF, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 8-(2-naphtholyl), and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is $-\text{CH}=\text{CH}_2$, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 25 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is $-\text{CH}=\text{CH}_2$, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Cyclopropyl, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 30 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-OMe)Ph, m

- is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is
(4-Benzyloxy)Ph, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl,
and X is O;
- 5 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is 4-Pyridinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 2-Thienyl, m is 1,
L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (2,6-diF)Ph, m
10 is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is -CH₂=CH₂, m is
1, L is -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is 7-F, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
- 15 a compound of formula (Ia) wherein R₁ is 5-F, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is H, m is 1, L is
20 -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is 6-F, R₂ is H, m is 1, L is
-CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is Cyclopropyl, m is 1,
L is -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
- 25 a compound of formula (Ia) wherein R₁ is H, R₂ is 3-thienyl, m is 1, L is
-CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is 2-thienyl, m is 1, L is
-CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is 3-furyl, m is 1, L is
30 -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is 2-furyl, m is 1, L is
-CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is 4-pyridinyl, m is 1, L

- is -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is 3-pyridinyl, m is 1, L
is -CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is
5 -CH₂CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is
-CH₂CH(Me)-, R₃ is (3-OMe-4-OH)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is
-CH(Me)CH₂-, R₃ is (3-OMe-4-OH)Ph, and X is S;
10 a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is
-CH₂CH₂-, R₃ is (3-OMe-4-OCH₂CH₂NH₂)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is
-CH₂CH(Me)-, R₃ is (3-OMe-4-OCH₂CH₂NH₂)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is
15 -CH(Me)CH₂-, R₃ is (3-OMe-4-OCH₂CH₂NH₂)Ph, and X is S;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is 4-pyridinyl, and X is S;
a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is 4-pyridinyl, and X is S;
20 a compound of formula (Ia) wherein R₁ is 6-Cl, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is 4-pyridinyl, and X is S;
a compound of formula (Ia) wherein R₁ is 6,7-diF, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is 4-pyridinyl, and X is S;
a compound of formula (Ia) wherein R₁ is 7-Cl, R₂ is Ph, m is 1, L is
25 -CH₂-, R₃ is 4-pyridinyl, and X is S;
a compound of formula (Ia) wherein R₁ is 5-Cl, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is 4-pyridinyl, and X is S;
a compound of formula (Ia) wherein R₁ is 8-Cl, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is 4-pyridinyl, and X is S;
30 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-OMe)Ph, m
is 1, L is -CH₂-, R₃ is 4-pyridinyl, and X is S;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (3-OMe)Ph, m
is 1, L is -CH₂-, R₃ is 4-pyridinyl, and X is S;

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-OMe)Ph, m is 1, L is $-CH_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 6,7-diOMe, R_2 is $-CH_2=CH_2$, m is 1, L is $-CH_2-$, R_3 is 4-pyridinyl, and X is S;
- 5 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is cyclopropyl, m is 1, L is $-CH_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-*t*-Bu, R_2 is (4-*t*-Bu)Ph, m is 1, L is $-CH_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-CF₃, R_2 is (4-CF₃)Ph, m is 1, L is $-CH_2-$, R_3 is 4-pyridinyl, and X is S;
- 10 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-CH_2-$, R_3 is 3-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 8-F, R_2 is Ph, m is 1, L is $-CH_2-$, R_3 is 2-pyridinyl, and X is S;
- 15 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-CH_2CH_2-$, R_3 is 4-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-CH_2CH_2-$, R_3 is 3-pyridinyl, and X is S;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-CH_2CH_2-$, R_3 is 2-pyridinyl, and X is S;
- 20 a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-CH_2-$, R_3 is (2-OMe-3-OH)-5-thienyl, and X is S;
- a compound of formula (Ia) wherein R_1 is 6,7-diF, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 25 a compound of formula (Ia) wherein R_1 is 8-Cl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6,7-diOMe, R_2 is $-CH_2=CH_2$, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- 30 a compound of formula (Ia) wherein R_1 is 6-*t*-Bu, R_2 is (4-*t*-Bu)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-CF₃, R_2 is (4-CF₃)Ph, m is

- 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-F, R₂ is (4-Cl)Ph, m is 1, L
is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-F, R₂ is (3-Cl)Ph, m is 1, L
5 is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-F, R₂ is (2-Cl)Ph, m is 1, L
is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is H, R₂ is (4-CF₃)Ph, m is 1, L
is a direct bond, R₃ is 5-isoquinoliny, and X is O;
10 a compound of formula (Ia) wherein R₁ is H, R₂ is (3-CF₃)Ph, m is 1, L
is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is H, R₂ is (2-CF₃)Ph, m is 1, L
is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is H, R₂ is (3-OMe-4-OH)Ph, m
15 is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is H, R₂ is (3-OH-4-OMe)Ph, m
is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe-7-OH, R₂ is Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
20 a compound of formula (Ia) wherein R₁ is 6-OH-7-OMe, R₂ is Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-Me, R₂ is Ph, m is 1, L is
a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-C(Me₂)CH₂Me, R₂ is Ph, m
25 is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-NO₂, R₂ is Ph, m is 1, L is
a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OSO₃Me, R₂ is Ph, m is 1,
L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
30 a compound of formula (Ia) wherein R₁ is 6-NHSO₂Ph, R₂ is Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-CO₂H, R₂ is Ph, m is 1, L
is a direct bond, R₃ is 5-isoquinoliny, and X is O;

- a compound of formula (Ia) wherein R_1 is 6-C(O)NH₂, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-C(O)NMe₂, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is 6-C(O)NHMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-CO₂Ph, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-cyclohexyl, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 6-Ph, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-NHC(O)(CH₂)₄-CH=CH-CH(Me)₂, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is H, R_2 is 2-pyridiny, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 3-pyridiny, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is H, R_2 is 4-pyridiny, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 3-thienyl, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 3-furyl, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 25 a compound of formula (Ia) wherein R_1 is H, R_2 is 2-furyl, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-hydroxynaphth-8-yl, and X is O;
- 30 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 1-hydroxynaphth-8-yl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 4-hydroxynaphth-8-yl, and X is O;


- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-hydroxynaphth-8-yl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-chloro-2-hydroxynaphth-8-yl, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 2,3-dihydroxynaphth-8-yl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-cinnolinyl, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-Me-5-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 4-(1,8-naphthyridinyl), and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-quinazolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 2-OH-5-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-OH-5-quinolinyl, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-F-5-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 3-Cl-5-quinolinyl, and X is O;
- 25 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 2-OH-3-Cl-5-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is $-\text{CH}_2=\text{CH}_2$, m is 1, L is a direct bond, R_3 is 5-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is $-\text{CH}_2\text{CH}_3$, m is 1, L is a direct bond, R_3 is 5-quinolinyl, and X is O;
- 30 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 8-Cl-5-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is 2-naphthyl, m is 1, L

- is a direct bond, R₃ is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1,3-diMe-5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 8-Cl-5-isoquinolinyl, and X is O;
- 5 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1,3-diMe-8-Cl-5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is isoquinolin-*N*-oxide-5-yl, and X is O;
- 10 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is -CH₂-, R₃ is 5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-quinolinyl, and X is O;
- 15 a compound of formula (Ia) wherein R₁ is 6-OH-7-OMe, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6,7-diOH, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-quinolinyl, and X is O;
- 20 a compound of formula (Ia) wherein R₁ is 6-OMe-7-OH, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-quinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-Cl-5-isoquinolinyl, and X is O;
- 25 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-Me-5-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-Me-5-isoquinolinyl, and X is O;
- 30 a compound of formula (Ia) wherein R₁ is 6-Br, R₂ is Ph, m is 1, L is a direct bond, R₃ is 8-isoquinolinyl, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 2-furyl, m is 1, L is a direct bond, R₃ is 5-isoquinolinyl, and X is O;

- a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 3-furanyl, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- 5 a compound of formula (Ia) wherein R₁ is 6-OCH₃, R₂ is 3-thienyl, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-OCH₃, R₂ is 2,4 di-F Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-OCH₃, R₂ is 2,4 di-F Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- 10 a compound of formula (Ia) wherein R₁ is 6-OCH₃, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- 15 a compound of formula (Ia) wherein R₁ is 6-Cl, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny-N-oxide, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 4-Cl- 5-isoquinoliny, and X is O;
- 20 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 4-Cl-5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 3-methyl-5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-methyl-5-isoquinoliny, and X is O;
- 25 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-Cl-5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-Cl, R₂ is Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny-N-oxide, and X is O;
- 30 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 4-CF₃ Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a

- direct bond, R₃ is 1,3-diCl- 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1,3-diCl-5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 8-Cl-5-isoquinoliny, and X is O;
- 5 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-piperidiny-5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-OCH₃-5-isoquinoliny, and X is O;
- 10 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-F- 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-N,N-dimethyl- 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-Cl, R₂ is nil, m is nil, R₃ is 1-CH₃-5-isoquinoliny, and X is O;
- 15 a compound of formula (Ia) wherein R₁ is 6-Cl, R₂ is nil, m is nil, R₃ is 1-Cl-5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 3-CF₃ Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- 20 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 3-CF₃ Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny-N-oxide, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 3-CF₃ Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny-N-oxide, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is spiro-2-indany, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- 25 a compound of formula (Ia) wherein R₁ is 6-F, R₂ is 4-Cl,3-CF₃ Ph, m is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-Cl, R₂ is Ph, m is 1, L is a direct bond, R₃ is 1-CH₃-5-isoquinoliny, and X is O; and
- 30 enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

91. A composition comprising a compound of Formula (Ia):

**Formula (Ia)**

said compound selected from the group consisting of

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- 5 a compound of formula (Ia) wherein R_1 is H, R_2 is 3-Pyridinyl, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- 10 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is $-\text{CH}_2-$, R_3 is (3,4-diOMe)Ph, and X is S;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 8-(2-naphtholyl), and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 20 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-Br, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 25 a compound of formula (Ia) wherein R_1 is 6,7-diOMe, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 7-Cl, R_2 is Ph, m is 1, L is a

- direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 5-Cl, R₂ is Ph, m is 1, L is a
direct bond, R₃ is 5-isoquinoliny, and X is O;
- 5 a compound of formula (Ia) wherein R₁ is H, R₂ is Ph, m is 1, L is a
direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (3-Cl)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6,7-diOMe, R₂ is Ph, m is 1,
L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- 10 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (2-Cl)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-Cl)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is H, m is 0, L is
15 a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (2-CF₃)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (3-CF₃)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- 20 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-CF₃)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is H, R₂ is -CH=CH₂, m is 1, L
is a direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-Br, R₂ is H, m is 0, L is a
25 direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-Cl, R₂ is H, m is 0, L is a
direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is
-CH₂-, R₃ is 5-isoquinoliny, and X is O;
- 30 a compound of formula (Ia) wherein R₁ is 7-Cl, R₂ is H, m is 0, L is a
direct bond, R₃ is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R₁ is 8-Cl, R₂ is Ph, m is 1, L is a
direct bond, R₃ is 5-isoquinoliny, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-CN)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-Br)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

5 a compound of formula (Ia) wherein R_1 is 6,7-diF, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is $-\text{CH}=\text{CH}_2$, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

10 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is $-\text{CH}=\text{CH}_2$, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;


a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (4-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-OMe)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

15 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is 2-Thienyl, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O; and

enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

20 92. A composition comprising a compound of Formula (Ia):



Formula (Ia)

said compound selected from the group consisting of

a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;


25 a compound of formula (Ia) wherein R_1 is 6-Br, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinolinyl, and X is O;

a compound of formula (Ia) wherein R_1 is 5-Cl, R_2 is Ph, m is 1, L is a

- direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is H, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-Br, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 5 a compound of formula (Ia) wherein R_1 is 6-Cl, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is Ph, m is 1, L is $-CH_2-$, R_3 is 5-isoquinoliny, and X is O;
- 10 a compound of formula (Ia) wherein R_1 is 7-Cl, R_2 is H, m is 0, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6,7-diF, R_2 is Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-F, R_2 is $-CH=CH_2$, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- 15 a compound of formula (Ia) wherein R_1 is 6-F, R_2 is 2-Thienyl, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O; and
- enantiomers, diastereomers, tautomers, solvates, and pharmaceutically accepted salts thereof.

20

93. A composition comprising a compound of Formula (Ia):



Formula (Ia)

said compound selected from the group consisting of

- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is Ph, m is 1, L is $-CH_2-$, R_3 is (3-OMe-4-OH)Ph, and X is S;
- 25 a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (3-Cl)Ph, m is 1, L is a direct bond, R_3 is 5-isoquinoliny, and X is O;
- a compound of formula (Ia) wherein R_1 is 6-OMe, R_2 is (2-Cl)Ph, m is

- 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (2-CF₃)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (3-CF₃)Ph, m is
5 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-CF₃)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O;
a compound of formula (Ia) wherein R₁ is 6-F, R₂ is Ph, m is 1, L is a
direct bond, R₃ is 3-Me-5-isoquinoliny, and X is O;
10 a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-Br)Ph, m is
1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O; and
a compound of formula (Ia) wherein R₁ is 6-OMe, R₂ is (4-OMe)Ph, m
is 1, L is a direct bond, R₃ is 5-isoquinoliny, and X is O.
- 15 94. A pharmaceutical composition comprising a compound, salt or
solvate according to claim 1 admixed with a pharmaceutically acceptable
carrier, excipient or diluent.
- 20 95. A veterinary composition comprising a compound, salt or solvate
according to claim 1 admixed with a veterinarily acceptable carrier, excipient or
dilluent.
- 25 96. A method of treating or preventing a disease or condition in a
mammal which disease or condition is affected by the modulation of one or
more vanilloid receptors, which method comprises administering to a mammal
in need of such treatment or prevention a therapeutically effective amount of a
compound, salt or solvate of claim 1.
- 30 97. A method for preventing or treating a chronic-pain causing
disease or condition, an acute-pain causing disease or condition, or a
pulmonary dysfunction comprising the step of administering to a mammal in
need of such treatment a therapeutically effective amount of a compound, salt
or solvate of claim 1.

98. A method for preventing or treating a disease or condition, wherein said disease or condition causes inflammatory pain, burning pain, itch urinary incontinence, or chronic obstructive pulmonary disease, said method
5 comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 1.

99. A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis,
10 fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, inflammatory
15 bowel diseases, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, Crohn's Disease,
20 ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate
25 neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual
30 cramps, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 1.

100. The method of claim 97 wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.

101. The method of claim 97 wherein said therapeutically effective
5 amount comprises a dose range of from about 0.1 mg to about 500 mg.

102. The method of claim 97 wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.

10 103. A kit comprising in one or more containers an amount of the composition of claim 1 effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder,
15 benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, inflammatory bowel diseases, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint
20 neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic
25 neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia,
30 nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma.

35 104. A pharmaceutical composition comprising a compound, salt or solvate according to claim 90 admixed with a pharmaceutically acceptable

carrier, excipient or diluent.

105. A veterinary composition comprising a compound, salt or solvate according to claim 90 admixed with a veterinarily acceptable carrier, excipient
5 or diluent.

106. A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in
10 particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, inflammatory
bowel diseases, pharyngitis, mucositis, enteritis, cellulites, peripheral
15 neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome,
20 oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic
25 neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma, said method comprising the step of administering
30 to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 90.

107. The method of claim 104 wherein said therapeutically effective

amount comprises a dose range of from about 0.001 mg to about 1,000 mg.

108. The method of claim 104 wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.

5

109. The method of claim 104 wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.

110. A kit comprising in one or more containers an amount of the composition of claim 90 effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, inflammatory bowel diseases, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma.

111. A pharmaceutical composition comprising a compound, salt or solvate according to claim 91 admixed with a pharmaceutically acceptable carrier, excipient or diluent.

112. A veterinary composition comprising a compound, salt or solvate according to claim 91 admixed with a veterinarily acceptable carrier, excipient or dilluent.

5

113. A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, inflammatory bowel diseases, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, irritable bowel syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of claim 91.

114. The method of claim 111 wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.

115. The method of claim 111 wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.

5 116. The method of claim 111 wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.

117. A kit comprising in one or more containers an amount of the composition of claim 91 effective to treat or prevent a disease or condition
10 selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact
15 dermatitis/hypersensitivity, itch, eczema, anxiety, panic disorders, inflammatory bowel diseases, pharyngitis, mucositis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain,
20 bony fractures, post-operative ileus, irritable bowel syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's
25 neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus
30 headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma.


Figure 1




Figure 2

Figure 3**Figure 4**

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/15254

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C275/26 C07C275/32 C07C335/14 C07D213/36 C07D215/38
C07D217/02 C07D217/08 C07D217/22 C07D217/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal; WPI Data, BIOSIS, MEDLINE, EMBASE, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TRIVEDI B K ET AL: "A series of conformationally and sterically constrained analogs of N-phenyl-N'-aralkylurea acat inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 5, no. 19, 5 October 1995 (1995-10-05), pages 2229-2234, XP004135289 ISSN: 0960-894X</p> <p>page 2231; examples 6,9; table 1</p> <p style="text-align: center;">--- -/--</p>	<p>1-4,6-9, 11-13, 20-22, 24-28, 30-34, 42-45, 47-50, 52-56, 72-76, 78-82, 84-88</p>



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

5 September 2003

Date of mailing of the international search report

17/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kiernan, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/15254

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 51970 A (FUJISAWA PHARMACEUTICAL CO (JP)) 8 September 2000 (2000-09-08) page 18; example 10	1-4,6,7, 9,11-13, 24,25, 27,28, 30,31, 33,34, 42,43, 45,47, 48,50, 52,53, 55,56, 72,73, 75,76, 78,79, 81,82, 84,85, 87,88
X	BAMBERGER, E. ET AL.: "Ueber beta-tetrahydrophthylamin " CHEM. BER., vol. 21, 1988, pages 847-860, XP009016746 page 858, last paragraph page 859, paragraph 1	1-4,6,7, 9,11-13, 24,25, 27,28, 30,31, 33,34, 42,43, 45,47, 48,50, 72,73, 75,76, 78,79, 81,82, 84,85, 87,88
A	WO 02 16318 A (PACIFIC CORPORATION) 28 February 2002 (2002-02-28) cited in the application abstract page 41, Scheme 32 page 194; example 182	1-117
A	LEE J ET AL: "N-(3-Acyloxy-2-Benzylpropyl)-N'-Dihydroxy tetrahydrobenzazepine and Tetrahydroisoquinoline Thiourea Analogues as Vanilloid Receptor Ligands" BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 9, 2001, pages 1713-1720, XP002244787 ISSN: 0968-0896 the whole document	1-117

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/15254

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WALPOLE C S J ET AL: "THE DISCOVERY OF CAPSAZEPINE, THE FIRST COMPETITIVE ANTOAGONIST OF THE SENSORY NEURON EXCITANTS CAPSAICIN AND RESINIFERATOXIN" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 13, 24 June 1994 (1994-06-24), pages 1942-1954, XP000576031 ISSN: 0022-2623 cited in the application the whole document -----</p>	1-117

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/15254

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 96-102, 106-109 and 113-116 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/15254

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0051970	A	08-09-2000	AU 2325700 A	21-09-2000
			BR 0010225 A	22-01-2002
			CA 2371827 A1	08-09-2000
			CN 1341095 T	20-03-2002
			EP 1159258 A1	05-12-2001
			HU 0200116 A2	29-05-2002
			WO 0051970 A1	08-09-2000
			JP 2002538132 A	12-11-2002
			TR 200102494 T2	21-01-2002
			US 2003096847 A1	22-05-2003
WO 0216318	A	28-02-2002	AU 8022901 A	04-03-2002
			AU 8023001 A	04-03-2002
			CA 2417507 A1	28-02-2002
			CN 1418191 T	14-05-2003
			EP 1303483 A1	23-04-2003
			EP 1311478 A1	21-05-2003
			WO 0216318 A1	28-02-2002
			WO 0216319 A1	28-02-2002
			KR 2002039226 A	25-05-2002
			KR 2002030009 A	22-04-2002
			US 2003153596 A1	14-08-2003